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Sjögren’s syndrome (SS) is a rheumatic autoimmune disease with yet unknown etiology. SS 
is characterized by sicca symptoms caused by involvement of the exocrine glands, mainly dry 
mouth (xerostomia) and dry eyes (keratoconjunctivitis sicca). In SS glands secretory acinar 
cell function is impaired and acinar cells are lost leading to diminished secretion of the 
glands, and a coexistent ductal cell hyperplasia is seen. SS is a strongly female dominant 
disease (9/10 of patients being women) and the diagnosis usually takes place between the ages 
of 40 and 50 years.  
 
In humans and other primates the synthesis of sex steroids takes place in the gonads as well as 
in peripheral tissues such as adipose tissue, prostate and breast tissue. This local synthesis, 
called intracrine synthesis occurs from adrenal gland derived pro-hormones 
dehydroepiandrosterone (DHEA) and androstenedione by the intracrine steroidogenic 
enzymatic machinery and can lead to synthesis of either androgens or estrogens according to 
local needs. Aging affects hormonal production, especially in women. After menopause the 
gonadal estrogen synthesis ceases and simultaneously the synthesis of the pro-hormones from 
the adrenal cortex decreases. SS diagnosis is often done at the time of these hormonal 
alterations. Accordingly, the late onset of SS combined with the gender-bias encourage to 
believe that sex steroids have a role in the etiology and progression of SS. 
 
Before this thesis primary observations about low serum DHEA levels in SS patients had been 
published. Our earlier studies showed diminished expression and secretion of androgen-
regulated biomarker cysteine-rich secretory protein 3 (CRISP-3) all over SS salivary glands, 
also in areas remote of lymphocyte infiltrates. This led to the assumption that hormonal 
imbalance, more specifically depletion of immunoprotecting androgens, could be one of the 
factors behind SS. We hypothesized that SS patients suffer from androgen depletion both 
systemically but in particular locally in salivary glands. We believed that this hormonal 
imbalance in the exocrine glands could lead to structural changes and further to functional 
defects in SS salivary glands. Accordingly, the aim of these studies was to clarify the role of 
sex steroids in SS and thus to elucidate some of the so far obscure etiopathology of the 
disease. The main analytical methods used were quantitive polymerase chain reaction (qPCR) 
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on messenger RNA (mRNA) level and immunofluoresence stainings, enzyme-linked 
immunosorbent assay (ELISA) and Western blotting on protein level.  
 
We confirmed our hypothesis and showed that SS patients have lower concentrations of 
DHEA, testosterone and dihydrotestosterone (DHT) both systemically in serum and locally in 
saliva compared with age- and sex-matched healthy controls. We especially focused on local 
hormonal enviroment in salivary glands and demonstrated for the first time that healthy 
salivary glands contain complete enzymatic machinery for local intracrine sex steroid 
synthesis. In SS salivary glands this machinery was found to be defective and, in a subgroup 
of patients, practically non-functional suggesting differencies between different SS patients. 
DHEA replacement therapy was found unbeneficial for SS patients, possibly due to the local 
defect in DHEA processing. 
 
After discovering the androgen depletion in SS the effect of this defect on salivary glands was 
studied. We found that in salivary gland cells and healthy labial salivary glands androgens 
regulate integrin subunits α1 and α2, important for communication, differentiation and 
function of acinar cells. On the contrary, in SS salivary glands DHEA failed to upregulate 
these signaling molecules. This finding highlights the importance of local androgen 
environment and intracrine processing for the function and welfare of salivary glands. 
 
To conclude, this study shows that patients with SS are androgen depleted both systemically 
and locally in salivary glands. SS patients also have a defective local intracrine sex steroid 
synthesizing enzymatic machinery further impairing the local androgen depletion. We also 
showed a tentative connection of androgen depletion and faulty intracrine activity with 
structural changes seen in SS salivary glands, thus linking hormonal imbalance to acinar loss 
and impaired glandular structure and function. In this study we have clarified some 
etiopathogenetic mechanisms of SS, which have thus far remained obscure, by showing the 
eventual importance of sex steroid imbalance in the onset and progression of SS.  
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4. REVIEW OF THE LITERATURE 
 
4.1. Sjögren’s syndrome 
 
SS is a chronic autoimmune rheumatic disease, which occurs almost exclusively in women 
with the female-to-male ratio being 9-to-1 and the majority of the diagnoses being made in 
the fourth or fifth decade of life. According to the current consensus SS is always 
characterized by focal adenitis and/or serum antibodies of the SS-A/Ro and SS-B/La type. In 
addition to these obligatory autoimmune features the syndrome is characterized by 
dysfunction and atrophy of the acinar cells of the exocrine glands, particularly salivary and 
lacrimal glands, leading to diminished secretory capacity of the glands and further to main 
symptomatic features of the syndrome, oral and lacrimal dryness (xerostomia and 
keratoconjunctivitis sicca, respectively) (Vitali et al., 2002). As a result of mucosal dryness, 
patients with SS are affected by local complications such as caries and oral candidosis more 
often than healthy controls (Soto-Rojas et al., 1998). Although the disease is mainly targeting 
salivary and lacrimal glands, all other exocrine glands of the human can be involved as well. 
Besides oral and ocular symptoms, Sjögren’s syndrome can also lead to manifestations in 
upper airways and genitals, for example (Freeman et al., 2005; Haga et al., 2005). SS can 
exist either in primary or secondary form (pSS and sSS, respectively). pSS evolves without 
co-existing autoimmune rheumatic disease, whereas in secondary form there is a verification 
of another underlying autoimmune disease in addition to and preceding SS, the highest degree 
of overlap occuring with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and 
systemic sclerosis (SSc) with RA being the most common one (Vitali et al., 2002; Ramos-
Casals et al., 2007). 
 
In addition to the glandular sicca symptoms, patients with SS suffer from diverse non-
exocrine systemic and visceral symptoms and complications demonstrating that this is a 
systemic autoimmune disease.  
 
The most disturbing and probably most disabling non-exocrine symptom is chronic fatigue. In 
Multidimensional Fatigue Inventory questionnaire (MFI-20; Smets et al., 1995) measuring 
general, physical and mental fatigue, reduced motivation and reduced activity SS patients 
scored 15.6 in a scale from 4 (no fatigue) to 20 (maximal fatigue) compared with a score of 
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8.2 in healthy age-matched women (Barendregt et al., 1998). In some patients fatigue may 
have an apparent reason, such as impaired quality of sleep as a result of aches and pains, 
disturbing xerostomia and polydipsia and nocturia which may wake up the patient several 
times each night and lead to non-restorative sleep and early morning fatigue. Some other 
patients may suffer from anemia, actively ongoing inflammation and acute phase response or 
autoimmune thyroiditis, in which cases the patient usually wakes up refreshed but develops 
early afternoon fatigue when they run out of energy.  
Psychiatric symptoms of SS such as anxiety and depression are closely connected with 
fatigue. Therefore, health-related quality of life in patients with SS is lower than in general 
population (Baturone et al., 2009; Segal et al., 2009). However, in most cases the reason and 
pathogenesis of fatigue in SS patients are still unknown.  
 
Systemic manifestations of SS can be divided into non-visceral (fatigue, arthralgia, myalgia, 
Raynaud’s phenomenon or “white fingers”, skin) and visceral symptoms (lungs, heart, 
kidneys, gastrointestinal tract, endocrine, nervous system) (Fox, 2005). In addition, patients 
with SS have an increased, even over 40 times higher than normal, risk for lymphoma, with 
patients with pSS having a higher risk than those with the sSS (Kauppi et al., 1997; Davidson 
et al., 1999; Theander et al., 2006). Certain risk factors such as mixed cryoglobulinemia, 
palpable purpura, low C4 and peripheral neuropathy predict the development of malignant 
lymphoma in SS patients. Mortality in SS is slightly increased compared to general 
population and is mostly explained by remarkably high incident of lymphoma (Voulgarelis 
and Skopouli, 2007; Voulgarelis and Tzioufas, 2010). 
 
Due to varying diagnosis criteria over time and in different countries the estimates of the 
prevalence of SS have fluctuated. However, according to studies made using the current, 
widely accepted classification criteria (Vitali et al., 2002) the prevalence of pSS has been 
estimasted to be around 0.1-0.6 %, 0.15 % or 0.72 % (Bowman et al., 2004; Andrianakos et 
al., 2003; Kabasakal et al., 2006, respectively). sSS is estimated to occur in 4-31 %, 9-19 % 
and 14-20 % of patients with RA, SLE and SSc, respectively (Andonopoulos et al., 1987; 
Nossent and Swaak 1998; Gilboe et al., 2001; Manoussakis et al, 2004; Avouac et al., 2006). 
SS is estimated to be one of the three most common autoimmune diseases together with RA 
and SLE (Pillemer et al., 2001). The criteria used in epidemiological studies affects the 
outcome and thus, due to different criteria, the prevalence of SS is difficult to estimate. 
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4.1.1. Diagnosis and assessment of Sjögren’s syndrome  
 
American- European consensus classification criteria are nowadays often used for the 
diagnosis of SS (Vitali et al., 2002). For a long time the diagnosis of SS was based on 
different criteria in Europe (Vitali et al., 1993) and USA (Fox et al., 1986) and classification 
criteria accepted in both continents were not available until the announcement of the current 
criteria in 2002 when the European criteria from 1993 were somewhat modified. 
Modifications were made considering the classification criteria, in particular the 
immunological features, which now are always required for the diagnosis based on the 
consensus criteria. Also classification of primary and secondary forms of the disease was 
sharpened in the American-European classification criteria (Vitali et al., 2002). 
 
The current American- European classification criteria define the ocular and oral symptoms, 
ocular signs and salivary gland involvement (Table 1). To confirm the diagnosis of pSS, the 
patient has to fulfill either four of the six criteria with IV (histopathology) and/or VI 
(serology) being positive or three of the four objective criteria (III-VI). In addition to the sicca 
symptoms and signs, a distinguishing feature of SS is the autoimmune nature of the disease. 
As mentioned above, unlike the pervious criteria, the current criteria always require an 
indication of autoimmunity in form of either autoantibodies (SS-A or SS-B) in serum or focal 
sialadenitis in labial salivary gland biopsy (focus score, the number of clusters of 50 or more 
lymphocytes per 4 mm2, must be ≥ 1). SS-A/Ro antibodies occur more commonly among 
patients with SS (with 30 to 70 % of patients being positive) than SS-B/La antibodies, which 
are less frequent (20 to 40 %) (Wahren-Herlenius et al., 1999). Diagnosis of sSS requires a 
verification of another underlying autoimmune disease according to currently valid criteria 
and a presence of either ocular or oral symptoms (I and II) added with two of the items III, IV 
or V (Table 1) (Vitali et al., 2002). Some characteristics not included in the classification 
criteria are the above mentioned female dominance, late onset of the disease, other sicca 
symptoms besides those of mouth and eyes and general and visceral symptoms and signs.  
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Table 1. Revised American-European classification criteria for SS (modified from 
Vitali et al., 2002). 
 
Symptom Definition 
I Ocular symptoms A positive response to at least one of 
the following: 
Continuous feeling of dry eyes for 
more than 3 months OR recurrent 
feeling of sand in the eyes OR use of 
tear substitutes more than 3 times a 
day 
II Oral symptoms A positive response to at least one of 
the following: 
Continuous feeling of dry mouth for 
more than 3 months OR persistently 
swollen salivary glands as an adult 
OR frequent drinking of liquids to aid 
in swallowing 
III Ocular signs A positive response to at least one of 
the following: 
Schirmer’s test ≤ 5 mm in 5 minutes 
OR Rose bengal score ≥ 4 according 
to van Bijsterveld’s scoring system 
IV Histopathology Focus score ≥ 1 in minor salivary 
glands, defined as a number of 
lymphocytic foci per 4 mm2 of 
glandular tissue 
V Salivary gland involvement A positive result in at least one of the 
following diagnostic tests: 
1) Unstimulated whole salivary flow 
≤ 1.5 ml in 15 minutes OR 
2) diffuse sialectasias in the parotid 
gland without evidence of obstruction 
in the major ducts OR 
3) delayed uptake, reduced 
concentration or delayed excretion of 
tracer shown by salivary scintigraphy 
VI Autoantibodies Presence in serum of one or both of 
the following autoantibodies: SS-
A/Ro, SS-B/La 
 
In addition to inclusion criteria, the American- European classification criteria provide 
exclusion criteria for SS, because SS needs to be distinguished from other conditions with 
specified cause affecting exocrine glands, such as human immunodeficiency virus and human 
hepatitis C virus infections. Besides these viral infections exculsion criteria include the use of 
anticholinergic drugs, past head and neck radiation treatment affecting the exocrine glands, 
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pre-existing lymphoma, sarcoidosis and graft versus host disease. The list of exclusion 
criteria, based on a list by Fox et al.  in a previous Californian (US) criteria for SS (Fox et al., 
1986) was improved in the new criteria. The following exclusions were added to the list: past 
radiation treatment of the head and neck, hepatitis C virus infection and the sentence “use of 
anticholinergic drugs” instead of “use of antidepressant, antihypertensive, parasympatholytic 
drugs and neuroleptic agents”. Additionally, sialoadenosis was deleted from the new 
exculsion criteria (Vitali et al., 2002). 
 
Besides making the diagnosis of SS somewhat complicated, the variable diagnosis criteria 
have also caused underdiagnosis and diversity in the estimations of the prevalence of SS and 
its various extraocular and extraoral features. In addition, the diagnosis has been made 
difficult by the fact that the SS diagnosis, like the diagnosis of many other rheumatic diseases, 
is based on the demonstration of several different manifestations instead of a single major 
feature. In retrospect, in individual patients it has often taken many years for the whole 
syndrome complex to evolve. The classification of SS in either primary or secondary form 
further complicates the diagnosis because it may in individual cases be difficult to 
differentiate between an underlying autoimmune disease and autoimmune visceral 
manifestations of the syndrome, not least because many autoimmune diseases are preceded by 
even many years long subclinical phase.  
 
Assessment of SS is challenging as well. The potentially reversible inflammation can lead to 
permanent damage in the affected glands and the distinction between SS activity and damage 
is thus difficult but essential. Other requirements of a valid assessment index include validity, 
reliability and sensitivity to change. Although separate criteria are used for the evaluation of 
SS activity and damage, the major weakness in the assessment of SS is the lack of an 
objective and standardised consensus criteria (Campar and Isenberg, 2010).  
 
As a consequence of the above-mentioned problems, diagnosis and assessment of SS is still 
challencing, especially in the beginning of the illness when the clinical picture is mild. A 
better understanding of etiology and pathomechanism of SS, incorporation of screening 
strategies and development of standardised assessment criteria are required for more reliable 
diagnosis and assessment.  
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The primary reason for SS is still obscure despite intensive research. Different factors 
suggested to contribute to the etiopathogenesis of SS include genetic background, epigenetics, 
dysfunction of autonomic nervous system and different environmental factors such as viral 
infections and hormonal factors (table 2). The epidemiology of pSS is strongly biased by both 
chronobiology and by gender, which suggests a role for sex steroids in the etiology of the 
syndrome. Before these thesis works, no studies had been reported in the literature on local 
salivary sex steroid levels in SS.  
 









Loiseau et al., 2001; Tzioufas et al., 2002 
Hulkkonen et al., 2001 
Miceli-Richard et al., 2007; Nordmark et al., 
2009 
Korman et al., 2008; Nordmark et al., 2009 
Epigenetics Stea et al., 2007 
Viruses 
Epstein-Barr virus 
Human T-cell leukemia virus 
 
Horiushi et al., 1999 
Terada et al., 1994 
Dysfunction of autonomic nervous system Santavirta et al., 1997 




Since no clear-cut singular reason has been found to SS, its pathogenesis is believed to be 
multifactorial. One of the most typical pathological findings in SS glands are local 
lymphocyte infiltrates (table 3). Another characteristic SS-feature is the presence of 
autoantibodies (table 3). SS-A/Ro and SS-B/La autoantibodies are directed towards a Ro-
ribonucleoprotein, the function of which is largely obscure but is believed to be in regulation 
of translation and post-translational modification (Fabini et al., 2000; Jonsson et al., 2007b).  
Besides the presence of glandular infiltrates and SS-autoantibodies, which are also included in 
the diagnostic criteria of the disease (Vitali et al., 2002), SS pathogenesis includes many other 
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factors. Levels of many proinflammatory cytokines and chemokines are increased in patients 
with SS (table 3). Besides infiltrating lymphocytes, also epithelial cells are considered to 
produce pro-inflammatory cytokines as part of the inflammatory response (Garcia-Carrasco et 
al., 2006). 
 
Other contributors in SS pathology are Toll like receptors (TLRs), which are considered to 
activate salivary gland epithelial cells and stimulate B cells (Gottenberg et al., 2006; 
Kawakami et al., 2007; Spachidou et al., 2007), and glandular epithelial cells themselves, 
which can have an active role in the pathogenesis of SS via unveiling of intracellular 
autoantigens and secretion of cytokines (Voulgarelis and Tzioufas, 2010) (Table 3). 
Characteristic findings in SS glands also include germinal centers (GC), in which the positive 
selection of autoreactive B-cells and thus the induction of autoimmunity are proposed to 
happen in GCs (Vinuesa et al., 2009).  
 
Table 3. Factors suggested to contribute to SS pathogenesis. 
 
Factor  References 




Katsifis et al., 2007; 
Manoussakis et al., 2007; 






Borda et al., 1996; Fabini et 
al., 2000; Ulbricht et al., 
2003; Jonsson et al., 2007b 
Cytokines TNF-α 
TGF-β 
IL-1, IL-6, IL-8, IL-17 
IFN-α, IFN-γ 
BAFF 
Koski et al., 1995; Pflugfelder 
et al., 1999; Xanthou et al., 
2001; Salomonsson et al., 
2002; Szodoray et al., 2003; 
Båve et al., 2005; Katsifis et 
al., 2007; Katsifis et al., 2009 
Toll-like receptors TLR2, -3, -4, -8 and -9 Gottenberg et al., 2006; 
Kawakami et al., 2007; 
Spachidou et al., 2007 
Epithelial cells  Voulgarelis and Tzioufas, 
2010 
Germinal centers Correlation with higher 
focus scores and 
productin of 
autoantibodies 
Salomonsson et al., 2003; 
Jonsson et al., 2007a Vinuesa 
et al., 2009 
 
One possible route for the pathogenesis of SS has been suggested to follow a path where a 
triggering factor in genetically predisposed individuals leads to invasion of the infiltrating 
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cells to exocrine glands. This invasion further causes apoptosis and/or necrosis of the 
glandular cells, reveals cryptic epitopes and is followed by the production of autoantibodies. 
Consequently, this further interferes with the glandular function. TLRs and increased 
secretion of proinflammatory cytokines may also contribute to the pathological process 
(Garcia-Carrasco et al., 2006). However, a definite pathway for the pathogenesis of SS has 
not been defined yet. The mechanism of the acinar atrophy and glandular destruction in SS is 
considered multifactorial and is believed to involve several cell types (inflammatory cells, 
epithelial cells) and molecules (cytokines, autoantibodies, TLRs and enzymes). Inflammation 
and deteriorated function of the exocrine glands may also represent separate processes in the 
pathogenesis of SS. 
  
4.1.3. Treatment of Sjögren’s syndrome 
 
Medical treatment of SS can be divided in two major divisions: local treatment for sicca 
symptoms and systemic treatment for extra-glandular manifestations. Most patients can 
manage with only local treatment (artificials tears, ocular ointments, topical non-steroidal 
anti-inflammatory drugs and chewing gum, sweets, artificial saliva for dry eyes and/or 
mouth). Local estrogens are used for genital dryness and epithelial atrophy (Jonsson et al., 
2007b; Ng and Isenberg, 2008).  
Systemic treatment includes the use of secretagogues, steroidal and non-steroidal anti-
inflammatory agents and disease-modifying and biologial agents. Pilocarpine and cevimeline, 
which are acetylcholine receptor agonists, have been shown to be beneficial in the treatment 
of oral and ocular dryness (Mavragani et al., 2006). Systemic corticosteroids are mainly used 
in the treatment of severe extra-glandular features, such as nervous system and renal 
manifestations. Patients with arthralgias or arthritis receive non-steroidal anti-inflammatory 
drugs. Treatment of extra-glandular changes and high systemic inflammatory activity also 
includes disease modifying and/or immunosuppressive drugs (hydroxychloroquinone, 
methotrexate). Of extra-glandular symptoms, the treatment of fatigue of patients with SS is 
most challenging. Recently there have been reports about positive effects of rituximab therapy 
on fatigue (Dass et al., 2008; Alcântara et al., 2009). 
 
Many novel candidates such as nizatidine (a H2 receptor antagonist), mizoribine (a suppressor 
of lymphocyte proliferation) and rebamipide (an anti-inflammatory mucosal protective agent) 
are promising as xerostomia and keratoconjunctivitis sicca therapies (Kapoor, 2009). Of new 
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potential medications in particular biological agents have been in focus of recent studies. 
Despite of the elementary role of TNF-α in inflammation and tissue damage in SS, anti-TNF 
therapies (infliximab, etanercept) have in controlled clinical trials proven unhelpful (Mariette 
et al., 2004; Ramos-Casals et al., 2010). Similarly, IFN-α proved to be only as effective as 
placebo, measured by stimulated whole saliva flow and oral dryness (Cummins et al., 2003). 
On the contrary, primary results from the use of B-cell targeting rituximab show some 
promise in some patients in both the treatment of SS and prevention of SS-associated 
lymphoma, although the adverse effects (infusion reactions, neutropenia, human antichimeric 
antibodies) can be significant. B-cell depletion therapy has also proven to improve stimulated 
and unstimulated whole saliva flow rate in a subset of patients with baseline salivary flow 
>0.1 ml/min. However, most studies show no changes in the objective measures of dryness 
with the rituximab treatment (Pijpe et al., 2005; Isaksen et al., 2008; Alcântara et al., 2009; 
Meijer et al., 2010). Especially extra-glandular manifestations have improved with rituximab, 
particularly in early stages of the disease (Dass et al., 2008; Alcântara et al., 2009). Also 
epratuzumab (anti CD-22 antibody) might be effective (Steinfeld et al., 2006). The 
mechanism of action of B-cell-targeted therapy might function via blocking antigen 
presentation by B cells to T cells or by preventing the secretion of B cell derived cytokines 
and autoantibodies. Anti-CD20 -therapy also works on memory B cells clustering in SS 
salivary glands, which do not proliferate and thus do not respond to therapies such as 
methotrexate mainly affecting proliferating cells. Future biological therapies may also target 
molecules like BAFF or IFN. 
 
Lack of consensus assessment criteria for SS, along with obscure etiology and disease 
process, complicates the interpretation and comparison of clinical trials studying new SS 
medications and thus complicates the treatment of SS. Accordingly, evidence-based therapy 
of SS is mainly limited to treatment of sicca symptoms. 
 
4.2. Sex steroids 
 
Sex steroids, androgens, estrogens and prostagens, are steroid hormones synthesized by a 
specialized endocrine tissue from where they are secreted into blood. From bloodstream they 
access their target cells and bind to specific receptors. Sex steroid –receptor complexes act by 
regulating gene expression of their target genes. On the other hand, in human and other 
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primates sex steroids can also be synthesized locally in the peripheral tissues from the adrenal 
gland derived pro-hormones DHEA, DHEA sulfate (DHEA-S) and androstenedione (Labrie 
et al., 2005). The main androgens produced in human are testosterone and DHT, an androgen 
with the greatest affinity towards the androgen receptor, whereas 17-β-estradiol is the most 
potent estrogen of the human body.  
 
Sex steroids affect both primary and secondary sexual characteristics. Physiological functions 
of estrogens include among others maintenance of bone mass, regulation of insulin 
responsiveness and regulation of lipoprotein synthesis in addition to regulating the 
development of female sex organs and characteristics. In men, estrogens have been found to 
be fundamental to fusion of epiphyses as well as to maintenance of bone mass (Nelson and 
Bulun, 2001). Androgens, for their part, have a pivotal role in male reproductive function. 
They also regulate pubertal development and contribute to secondary sexual characteristics in 
males (Quigley et al., 1995; Gelmann 2002). Testosterone, as well as androstenedione, also 
serves as precursors that can be aromatized into estrogens (Walters et al., 2008). In addition to 
their roles in reproductive processes, both estrogens and androgens are thus considered to 
have general metabolic roles in both sexes (Simpson, 2003). 
 
4.2.1. Synthesis and metabolism of sex steroids  
 
Sex steroids are cholesterol derivates. Both estrogens and androgens are synthesized from 
DHEA, which is derived from cholesterol (Figure 1). Synthesis of active sex steroids from 
DHEA goes through androstenediol and androstenedione with DHT and 17-β-estradiol as 
final products of the androgen and estrogen pathways, respectively. Gonads, testes and 
ovaries, are the primary synthesizers of sex steroids. Ovarian follicles and corpus luteum 
secrete mainly estrogens and progesterone, but also androgens are released. The primary 
source of androgens is the Leydig cells of the testes (Kroboth et al., 1999; Sanderson, 2006). 
 
In addition to synthesis in the gonads, humans synthesize sex steroids locally in peripheral 
tissues. This local synthesis stems from the unique feature of primates: they possess a 
reticular zone in their adrenal glands that secretes large amounts of so-called prohormones 
DHEA, DHEA-S and androstenedione. The cortex of the human adrenal glands consists of 
three layers, all with different functions. The outermost layer, zona glomerulosa and the 
middle layer zona fasciculata produce mineralocorticoids and glucocorticoids, respectively. 
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The innermost layer, zona reticularis, is the location of the synthesis of DHEA, DHEA-S and 
androstenedione (Hornsby, 2004). The synthesis of DHEA from cholesterol includes two 
steps: first, cholesterol is converted to pregnenolone after side chain cleavage by 
mitochondrial cholesterol side-chain cleavage enzyme (P450scc) in mitochondria, and 
subsequently pregnenolone is processed into DHEA through the action of steroid 17-α-
hydroxylase/17,20 lyase (P450c17) (Kroboth et al., 1999). DHEA can further be converted 
into DHEA-S, the most common circulating steroid hormone in human, by sulfotransferase 
(Figure 1) (Labrie, 2003). 
 
Adrenal gland derived precursor hormones constitute a large reservoir of substrate that can be 
processed into active estrogens or androgens extragonadally by steroidogenic enzymes 
according to local needs in different peripheral tissues (Labrie, 1991). These 
intracrinologically produced sex steroids function in the same cells in which they are 
produced without further release into blood (Nestler et al., 1988). Classical intracrine tissues 
include tissues such as prostata and mammary gland. Many other tissues, such as adipose 
tissue and bone, have been shown to produce sex steroids locally as well (Simpson, 2003).  
 
The first step in the transformation of DHEA into androstenedione (4-dione), a step common 
to synthesis of both androgens and estrogens, is catalyzed by 3β-hydroxysteroid 
dehydrogenase (3β-oli-dehydrogenase Δ4,5 –isomerase) (3-β-HSD). There are multiple 
isomers of this enzyme enabling the tissue- and cell specific regulation of the enzymatic 
activity. Also 17β-OH- steroid dehydrogenase (17-β-HSD) enzymes exist in multiple types, of 
which some catalyze the reductive reaction in the synthesis pathway and some work in the 
opposite direction thus inactivating androgens and estrogens. 5-α-reductase catalyzes the 5-α-
reduction of 4-dione to androstanedione and testosterone to DHT, the most active androgen. 
The synthesis of estrogens, namely 17-β-estradiol, is catalyzed by aromatase (Labrie et al., 
2005) (Figure 2). Processing of the adrenal precursor steroids into active androgens and/or 
estrogens in peripheral target tissues is depended on the expression levels of steroidogenic and 
sex steroid metabolizing enzymes in these tissues. 
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Figure 1. Synthesis of prohormones dehydroepiandrosterone (DHEA), DHEA-
sulfate (DHEA-S) and androstenedione from cholesterol in zona reticularis of the 
adrenal glands. P450scc = mitochondrial cholesterol side-chain cleavage enzyme 
(Cytochrome P450 11A1), P450c17 = Steroid 17-α-hydroxylase/17,20 lyase 
(Cytochrome P450 17A1), 3-β-HSD = 3β-hydroxysteroid dehydrogenase (3β-oli-
dehydrogenase Δ4,5 –isomerase), 17-β-HSD = 17-β-hydroxysteroid dehydrogenase 
(Modified from Miller, 2009). 
 
Local production of sex steroids is of extreme importance in human and 90 % of DHEA and 
98 % of DHEA-S in circulation are produced by the adrenal cortex (Knochenhauer and Azziz, 
2001; Labrie, 2003). Approximately 50 % of total androgens in the prostate of an adult man 
are synthesized in an intracrine fashion. In women the local intracrine synthesis is even more 
important: 75 % and nearly 100 % of peripheral estrogens in pre- and postmenopausal 
women, respectively, are synthesized locally (Belanger et al., 1986; Labrie, 1991). Total 
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androgen production, estimated from the measurement of the conjugated DHT metabolites 
which are considered to represent the most reliable parameters of the total androgen pool, in 
women represents two-thirds of the corresponding values in men and the majority of these 
androgens originate from the peripheral production (Labrie et al., 1997a). 
 
Sex steroids are metabolized first by phase I enzymes, after which phase II enzymes act on 
these metabolites forming conjugates that are usually more polar and thus more easily 
secreted by the kidneys. In the case of DHT, phase I metabolites include androsterone, 
epiandrosterone, androstane-3α,17β-diol (3-α-diol) and androstane-3 β,17β-diol, which are 
formed through the action of many 3-α/β-HSD and 17- β-HSD isoforms. For final metabolism 
of androgens phase II enzymes, such as UDP-glucuronosyltransferases, convert phase I 
metabolites further into conjugates, like androstane-3α,17β-diol-glucuronide (3-α-diol-G) and 
androsterone-glucuronide (ADTG), the two major phase II metabolites of DHT (Figure 2). 
In peripheral tissues, DHT is considered to be metabolized into conjugates locally before 
leaving the tissue and appearing in the circulation. Thus, as mentioned above, serum levels of 
these metabolites are considered to reflect the androgen status in the peripheral tissues and by 
controlling the metabolizing enzymes the androgen levels of these tissues can be regulated 
(Bélanger et al., 2003). 
 
Regulation of sex steroid synthesis 
 
Gonadal production of sex steroids is regulated by luteinizing hormone and follicle 
stimulating hormone (LH and FSH, respectively). Secretion of androgens from the Leydig 
cells is mainly regulated by LH (Franchimont, 1983). Sex steroid production in the ovaries is 
explained by the two-cell theory according to which LH induces the production of androgens 
from cholesterol in the theca cells while FSH stimulates the conversion of theca cell derived 
androgens to estrogens in the granulosa cells (Falck, 1959, Sanderson, 2006). 
 
Synthesis of sex steroid precursors from the adrenal glands is in part regulated by 
adrenocorticotropic hormone (ACTH) secreted from the pituitary gland. The hypothalamic 
corticotropin-releasing hormone (CRH) stimulates the secretion of ACTH, which further 
stimulates adrenal cortex to secrete gluco- and mineralocorticosteroids and adrenal precursor 
hormones (Kroboth et al., 1999). Also local factors in the adrenal cortex, such as cytokines 
derived from immune cells (macrophages, lymphocytes) and adrenal cells themselves 
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modulate the synthesis of adrenal prohormones (Ehrhart-Bornstein et al., 1998). The degree 
of the peripheral synthesis of sex steroids depends on the amounts of adrenal gland derived 




Figure 2. Peripheral androgen metabolism. Adrenal gland derived prohormones 
are converted to most active androgen, dihydrotestosterone, which is further 
metabolized and finally inactivated by UDP-glucuronosyltransferases. Subtypes of 
each HSD enzyme is marked with a number. DHEA = dehydroepiandrosterone, 
DHEA-S = dehydroepiandrosterone sulfate, G = glucuronide, HSD = 
hydroxysteroid dehydrogenase (Modified from Bélanger et al., 2003 and Konttinen 
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4.2.2. Mode of action of sex steroids  
 
Since sex steroids are hydrophobic, they circulate mostly bound to carrier proteins, which can 
be either general (with low affinity for steroids) or specific to steroids (with higher affinity). 
Only approximately 2 % of the total sex steroid amount in the circulation exists as a free 
fraction (Dunn et al., 1981). Albumin is the most common general carrier protein, whereas 
liver-derived sex-hormone binding globulin (SHBG) and corticosteroid-binding globulin 
(CBG) are specific carriers. Most serum androgens and estrogens are carried by SHBG and to 
a minor extent by albumin (Hammond et al., 2003; Michels and Hoppe, 2008). According to 
the free hormone hypothesis steroid hormones are thought to enter their target cells only from 
the free portion and not from the protein-bound portion. Thus, intracellular hormone 
concentrations have traditionally been considered to reflect the concentration of the 
corresponding free hormone in plasma (Mendel, 1992).  
 
To carry out their functions, steroids have been considered to diffuse through the plasma 
membrane and bind to their intracellular, mostly cytoplasmic receptors. Both androgens and 
estrogens act in the same manner: they bind to their receptors, translocate to the nucleus and 
mediate changes in the transcription of their target genes (Figure 3). Androgen and estrogen 
receptors (AR and ER, respectively) belong to the family of nuclear receptors and are ligand-
dependent transcriptional factors. The structure of AR and ER consists of three domains with 
different functions: a function-contributing variable N-terminal domain, ligand binding 
domain, which binds the steroid ligand and DNA binding domain which binds to target DNA 
(Evans, 1988; Gelmann, 2002). 
 
In addition to the classical mode of action through their nuclear receptors, androgens and 
estrogens can operate in rapid non-genomic manner and have an influence faster, within 
seconds to minutes either by binding with G-protein coupled receptors (membrane androgen 
receptors or sex-hormone binding globulin receptors) or by binding directly to their target 
proteins (ion-channels and transporters) (Falkenstein et al., 2000; Michels and Hoppe, 2008). 
Megalin is one receptor mediating non-conventional actions of sex steroids. It is able to bind 
SHBG-steroid complex thus enabling the entry of also that fraction of sex steroids bound to 
SHBG, previously considered “inactive” according to the free hormone hypothesis, into 
tissues (Hammes et al., 2005). Whether a steroid will induce a rapid or a genomic signal 
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Figure 3. Classical mode of action of sex steroids. Hormones enter the cell by 
passive diffusion and bind to the chaperone-bound nuclear receptor (NR). The 
binding of hormone to its receptor releases the chaperone and leads to receptor 
dimerisation. NR/hormone dimers translocate to the nucleus and bind to the 
hormone responsive element (HRE) on their target gene together with coactivators 
and RNA polymerase. The outcome of the hormonal effect is an alteration in the 
target gene expression. 
 
There are controversial opinions about the existence of specific receptors for DHEA. Specific 
receptors for DHEA have been suggested to exist in T-cells and vascular endothelial cells 
(Meikle et al., 1992; Liu and Dillon, 2004). Additionally, it has been shown that in 
endothelial cells, blocking of ER or AR did not inhibit DHEA-induced effects. However, 
these effects were reversed by inhibition of Gi/o-proteins, suggesting involvement of a 
specific plasma membrane, Gi-protein bound DHEA receptor other than ER or AR and a non-
genomic action of DHEA (Williams et al., 2004; Liu et al., 2008).  
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4.2.3.  Sex steroid imbalance and immunity 
 
Sex steroids have remarkable effects on the immune system. Estrogens stimulate 
immunoglobulin production in peripheral blood mononuclear cells and enhance humoral 
immunity (Kanda and Tamaki, 1999). Estrogens and their metabolites also have a positive 
effect on the secretion of proinflammatory cytokines (Janele et al., 2006). Contrary to the role 
of estrogens, testosterone was reported to inhibit secretion of proinflammatory cytokines such 
as TNF and IFN-γ (Janele et al., 2006). Testosterone also inhibited the production of 
antibodies by peripheral blood mononuclear cells both in normal persons and patients with 
SLE (Kanda et al., 1996; Kanda et al., 1997) and is suggested to inhibit IL-1 secretion by 
macrophages (Cutolo et al., 1995). Further support to the anti-inflammatory roles of 
androgens is given by the study showing that androgen therapy is effective in the treatment of 
RA (Cutolo et al., 1991; Booji et al., 1996).  
 
However, there are results showing opposite roles for estrogens and androgens. Besides 
stimulating antibody formation, estrogens have been suggested to be anti-inflammatory 
(Carlsten, 2005). Also, the effect of estrogens on immunity has been reported to depend on 
the concentration: low and high concentrations of estradiol in chronic inflammatory diseases 
are thought to be pro- and anti-inflammatory, respectively (Cutolo and Wilder, 2000). 
Testosterone has been reported to have proapoptotic effects on activated macrophages, where 
as 17-β-estradiol had opposite effects (Cutolo et al., 2005). Furthermore, estrogen deficiency 
as a result of aromatase depletion has been suggested to cause a SS like disease in mice (Shim 
et al., 2004) and estrogen deficiency has been reported to induce apoptosis resticted to 
tubuloacinar cells, which may induce α-fodrin autoantibodies and a SS-like condition in mice.  
 
Besides the immunomodulatory role of active estrogens and androgens, pro-hormones DHEA 
and androstenedione are reported to be immunomodulatory per se or by virtue of their 
metabolites. Studies suggest them to enhance the immune function and protect mice from 
microbial infections (Padgett et al., 1995). Additionally, DHEA supplementation has been 
shown to decrease T helper cells and increase natural killer cells in postmenopausal women as 
well as to increase monocytes, B-cells and T-cell activation in older men (Casson et al., 1993; 
Khorram et al., 1997). Consequently, DHEA has been proposed to participate in the 
activation of the immune system. DHEA has also been shown to inhibit formation of murine 
autoantibodies in SLE mouse model (Lucas et al., 1985). 
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4.3. Salivary glands  
 
Salivary glands are branched saliva producing glands belonging to exocrine glands, which 
also include pancreas, liver and gall bladder in the digestive tract. The secretions from these 
glands are directed to the lumen of the digestive tract, where they operate mostly in digesting 
food. 
 
4.3.1. Anatomy and histology of salivary glands  
 
There are two types of salivary glands in humans and other mammals: three pairs of main 
salivary glands (submandibular, sublingual and parotid gland located under the mandible, 
under the tongue and between the upper and lower jaw in the back of the mouth, respectively) 
and a large number of minor salivary glands with a short salivary duct, located directly under 
the oral mucosa. Salivary glands share a common structure with saliva producing acini in the 
end of the branches, ducts, which deliver the secreted saliva from the acinus into oral cavity 
and connective tissue surrounding the gland (Tucker, 2007). Ducts can be divided into 
intercalated ducts located next to the acini, striated ducts and finally excretory ducts leading 
to the oral cavity (Figure 4). Ducts of the parotid gland are long and open opposite to the 
upper second molar. Saliva from the submandibular and sublingual glands is drained under 
the tongue and in the floor of the mouth, respectively (Ogawa, 2003; Tucker, 2007). Minor 
salivary glands have similar structure with acini and ducts. These glands are small and also 
ducts of the minor glands are short. 
 
Basement membrane in salivary glands 
 
As every tissue, also salivary glands are surrounded by extracellular matrix (ECM), which is 
an extracellular part of tissues providing structural support to cells, having also other 
functions (Figure 4). 
 28
Review of the literature 
 
 
Figure 4. Schematic picture of a salivary gland. Saliva secreting acinus consists of 
acinar cells and salivary duct of intercelated ductal cells located next to the acinus 
and striated ductal cells located closer to the oral cavity. Basement membrane 
surrounds the gland. 
 
Basement membrane (BM) is a specialized part of the ECM directly underlying epithelial and 
endothelial cells and separating them from the interstitial stroma. BM consists mostly of 
laminin and collagen type IV connected together by nidogen-1 and perlecan (LeBleu et al., 
2007). BM does not only act passively in supporting cells but has also a functional role. BM 
serves as a storage of information and growth factors and influences and modifies cellular 
morphogenesis, differentiation, growth and functionality through outside-in signalling in 
salivary glands as in other glandular tissues (Ekblom et al., 1998; LeBleu et al., 2007).  
 
Laminins represent the major protein components of BM. They are large heterotrimeric 
glycoproteins composed of one of five α, three β and three γ chains, bound together by 
disulfide bonds to form usually cross-like structures with three short and one long arm 
(Aumailley et al., 2005). In salivary glands, ductal and acinar parts of the BM express 
different laminin compositions. Laminin α2 chain is considered characteristic for the 
myoepithelial cells (Strassburger et al., 1998), whereas α1 is seen in specifically acinar BMs 
apparently in contact with secretory acinar cells (Laine et al., 2004). Laminin α3, α5, β1, γ1 
and γ2 chains are found both in ductal and acinar compartments. Laminins represent probably 
the major instrument of communication between BM and epithelial cells. They store 
information and upon binding to cellular receptors, such as integrins and dystroglycan, deliver 
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messages from BM to cells. Especially integrins have a pivotal role in the interaction of cells 
with the BM. Except for laminins, integrins serve as receptors for other ECM proteins and 
cell surface adhesion molecules. They are expressed in different heterodimeric combinations 
of α and β subunits with different ligand specificities (Lourenço and Kapas, 2005). Like 
laminins, also integrins have different expression patterns in different parts of salivary glands 
with α1 and α2 subunits representing acinar integris and α3, α6, β1 and β4 subunits being 
expressed both in acinar and ductal compartments (Laine et al., 2008). 
 
Interactions between BM constituent laminins and their cellular integrin receptors are crucial 
for salivary glands. They operate in branching morphogenesis and the functional 
differentiation of salivary gland cells (Kadoya et al., 1997; Durbeej et al., 2001: Lam et al., 
2005; Lourenço and Kapas, 2005; Szlávik et al., 2008). Interactions between integrins and 
BM ligands lead to a variety of signalling responses such as changes in calcium influx, 
cytoplasmic pH, phospolipase activity and protein phosphorylation in the cell (Lafrenie and 
Yamada, 1998). In addition, integrins also function as biosensors of BM composition and 
control the survival or programmed death of the cell (Stupack and Cheresh, 2002). 
 
4.3.2. Saliva  
 
Saliva is an exocrine fluid consisting mainly (approximately 99%) of water. Other 
components of saliva include a variety of electrolytes (sodium, potassium, calcium, 
magnesium, bicarbonate, phosphates), proteins such as immunoglobulins, antimicrobial 
peptides, enzymes and mucins and nitrogenous products like ammonia and urea. Whole saliva 
is a mixture of secretions from both major and minor salivary glands added with gingival 
fluid containing bacteria and food debris, epithelial and blood cells as well as traces of 
medicines and chemical products (Ogawa, 2003; Tucker, 2007).  
 
Main functions of saliva 
 
Saliva has multiple functions with its three main roles being lubrication and protection of oral 
tissues, antimicrobial properties and buffering of acid attacks. By lubricating oral tissues 
saliva facilitates the movements of lips and tongue thus aiding swallowing and speaking. The 
protective role of saliva includes inhibiting carcinogens and plaque-derived proteolytic and 
other hydrolytic enzymes from causing damage. The lubricating and protecting function relies 
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in particular on mucins, which comprise approximately a quarter of the salivary proteins. 
Mucins are complex glycoproteins existing in salivary glands predominantly in two forms, the 
high-molecular-weight (oligomeric) MG1 and the low-molecular-weight (monomeric) MG2 
(Saari et al., 1997; Zalewska et al., 2000; Humphrey and Williamson, 2001).  
 
Mucins also participate in the antimicrobial role of saliva. They offer a major binding site for 
microorganisms entering the mouth aggregating them and thus inhibit microorganisms from 
reaching oral tissues. Other antimicrobial agents of saliva include molecules (lactoferrin, 
lysozyme, peroxidase) inhibiting bacterial growth and destroying them, proteins and peptides 
aggregating bacteria and secretory immunoglobulins, mainly secretory IgA blocking adhesion 
of bacteria to host tissues. In addition to IgA, phagocytosis-enhancing IgG and IgM exist in 
saliva. Additionally, the flushing effect of saliva from mouth to gut is as such an important 
protective factor against microbes (Tenovuo 1998; Humphrey and Williamson, 2001). 
 
The buffering capacity of saliva, too, serves to protect the mouth from microbes. The main 
component of the salivary buffering system is bicarbonate which diffuses into plaque and 
neutralizes acids. Furthermore, bicarbonate generates ammonia form amines, thus adding the 
neutralizing effect. In addition to the bicarbonate system, phosphates and the protein system 
buffer saliva. The buffering capacity of saliva also serves as a factor in maintenance of tooth 
integrity by facilitating remineralization and inhibiting caries progression. Other functions of 
saliva include enhancing taste and digesting food (Humphrey and Williamson, 2001).    
 
Secretion of saliva 
 
Salivary glands are innervated by both parasympathetic and sympathetic nerves. With major 
glands, the secretion of the watery and organic component of saliva is generated by 
parasympathetic and sympathetic stimulation, respectively (Garrett, 1987). A salivary center 
in the medulla controls the secretion and can be stimulated by mechanical, gustatory and 
olfactory stimuli. In addition, psychic factors and certain medications affect the secretion. 
Main salivary glands are responsible for the saliva production and they produce 
approximately 90 % of the saliva with 20 % coming from the parotid, 65 % from the 
submandibular and 7 to 8 % from the sublingual gland. Minor salivary glands produce the 
remaining 10 %. The relative contribution of different salivary glands changes between 
unstimulated and stimulated salivary flow so that minor salivary glands produce 
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proportionally more during rest whereas the parotid gland is responsible for approximately 50 
% of the stimulated salivary production (Humphrey and Williamson, 2001). In addition to 
their volume main salivary glands also differ in the type of saliva they produce. Acini can be 
divided into serous and mucous: serous acinar cells secrete watery secretion with a large 
amount of proteins whereas mucous cells secrete mucous saliva with large glycoproteins 
called mucins. Parotid gland is a serous gland whereas the sublingual glands are mucous. 
Submandibular gland is a seromucous gland producing saliva with both proteins and mucins.  
 
Stimulation of myoepithelial cells by the autonomous nerves results in the contraction of 
these cells surrounding acini and some parts of the ducts generating movement of the 
secretion (Tucker 2007). Upon contraction, the protein- or carbohydrate -rich granular content 
of serous and mucous acinar cells, respectively, is secreted in parallel with water and 
electrolytes. This secretion, primary saliva, is consequently forced out of the acini into the 
ducts, which collect and transport the secretion to the oral cavity. Striated and excretory 
ductal cells also modify primary saliva: they reabsorb Na+ and Cl- and secrete low amounts of 
K+ and HCO3-. Due to the low permeability of the ducts to water, the secondary saliva 
secreted to the oral cavity is hypotonic compared to primary saliva. Intercalated ductal cells 
do not take part in processing of primary saliva (Humphrey and Williamson, 2001; Ogawa, 
2003; Tucker, 2007).  
  
The molecular mechanisms leading to the production of primary saliva involve activity of 
four ion channels. In the resting phase, basolateral ion pumps Na+,K+,2Cl- –cotransporter and 
Na+/K+ ATPase pump Cl- and K+ into acinar cell. The activation of either cholinergic or α-
adrenergic receptors leads to increased release of Ca2+ from endoplasmic reticulum into the 
cytosol. Ca2+ further activates Ca2+ sensitive basolateral K+ and apical Cl- channels leading to 
leakage of these ions into circulation and to the lumen of the acinus, respectively. Release of 
K+ hypopolarizes/sensitizes the acinar cells. Na+ follows Cl-, and water is consequently 
secreted according to the osmotic gradient into the lumen through apical aquaporin channels 
and between the cells. After the stimulation, concentration of Ca2+ decreases followed by 
elevation of Na+ concentration due to the activity of both Na+-H+ exchanger and Na+ -coupled 
transport of Cl- and K+. This flow of ions induces the uptake of water to the cell. Also 
reuptake of K+ and Cl- follow (Nauntofte, 1992).  
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The average amount of whole saliva secreted is between 0.5 and 1.5 liters a day with a 
remarkable variability between individuals. Any amount of unstimulated salivary secretion 
above 0.1 ml/min is normal and salivary flow less than that is considered hyposalivation. For 
stimulated saliva the corresponding limit is 0.7 ml/min.  
 
Aging as such does not cause hypofunction of the salivary glands. Instead, systemic diseases 
and increased use of medicines in the elderly people are believed to induce reduced salivary 
flow as a side effect (Baum, 1981; Parvinen and Larmas, 1982). However, in aging 
individuals the acinar glandular tissue of salivary glands is replaced with fatty and fibrous 
tissue leading to reduction of acinar components and further to diminished salivary gland 
function (Nagler, 2004). Indeed, results implying a reductive role for aging in salivary flow 
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5. AIMS OF THE STUDY  
 
Regardless of its relatively high prevalence and intensive research, the pathogenesis of SS is 
still obscure. The female dominance, late onset and targeting of the disease into all exocrine 
glands encouraged us to hypothesize that sex steroids, especially androgens, play an important 
role in the emergence and progression of SS. The aim of these studies was to clarify some 
roles of sex steroids in the etiology and pathogenesis of SS with the following specific 
objectives: 
 
1. To test our hypothesis about androgen defect in SS by examining the androgen and 
estrogen levels in healthy controls and in patients with SS both systemically in serum and 
locally in saliva  
 
2. To investigate the local DHEA-S processing intracrine enzymatic machinery in vitro and in 
vivo in healthy and SS salivary glands by studying its expression and function and the 
capability of oral DHEA replacement therapy to normalize systemic and, more importantly, 
local salivary levels of androgens in SS patients 
 
3. To study if oral DHEA benefits SS patients with severe fatigue and low serum DHEA-S 
concentration 
 
4. To study the effect of androgens on the expression of laminin-111 and integrins α1β1 and 
α2β1, which are important for salivary gland acinar cell differentiation and signalling in order 
to study the connection between androgen deficiency and acinar atrophy seen in SS salivary 
glands
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6. MATERIALS AND METHODS 
 
6.1. Cell cultures 
 
6.1.1. Cell line (I, V) 
 
HSG is an irradiated neoplastic intercalated ductal cell line derived from the human 
submandibular gland (Shirasuna et al., 1981). The cell line can be induced to express an 
acinar phenotype by culturing it on basement-membrane mimicing, laminin α1 chain 
containing Matrigel (BD Biosciences, San Jose, CA) (Royce et al., 1993). Cells were cultured 
in DMEM/F-12 Nut Mix medium (Gibco BRL, Grand Island, NY) supplemented with 10 % 
fetal calf serum, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin in 5% 
CO2-in-air at + 37°C. 
 
6.1.2. Cell stimulations (I, V) 
 
For stimulations, HSG cells were grown in 6- or 24-well-plates with number of cells per well 
being 3 x 105 or 5.5 x 104, respectively. Cells grown in wells without or with Matrigel coating 
(BD Biosciences, San Jose, CA) (ductal and acinar phenotypes, respectively) were stimulated 
with 1, 10 or 100 μM DHEA (Fluka, St. Louis, MO; Sigma-Aldrich, St.Louis, MO) (I, V), 1 
μM testosterone (Sigma-Aldrich, St.Louis, MO) (V), 1, 10, 100 or 1000 nM DHT (Fluka, St. 
Louis, MO; Sigma-Aldrich, St.Louis, MO) (I, V) or 100 nM 17-β-estradiol (Sigma-Aldrich, 
St.Louis, MO) (V). Stimulations were performed in serum-free media for 72 hours. Every 
stimulation was done in triplicate or multifold. After the stimulations, culture media were 
collected and stored in -70 ºC. 
Inhibitor of 5-α-reductase types I and II (Dutasteride; GlaxoSmithKline, Middlesex, UK) or II 
(Finasteride; Sigma-Aldrich, St. Louis, MO) was added at the same time as the hormones (I).  
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6.2. Patients and samples (I-V) 
 
Table 4. Subjects of the studies. In healthy controls the diagnosis of primary SS 
was refuted using the American-European consensus criteria (Vitali et al., 2002). 
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 6.3. Tissue cultures (I, II, V) 
 
The samples were minced into pieces (approximately 2 mm3), put into a 6-well-plates and left 
overnight in DMEM/F-12 medium (Gibco BRL, Grand Island, NY) containing 10 % fetal calf 
serum with 2mM L-glutamine, 1000 U/ml penicillin, 1 mg/ml streptomycin (10X) and 
Fungizone (2.5 µg/ml) (Gibco BRL, Grand Island, NY) solution. The next day, the media 
were changed to basal DMEM/F-12 media with 10 % serum-stripped fetal calf serum, 2 mM 
L-glutamine, 100 U/ml penicillin, 0,1 mg/ml streptomycin (1X solution) and 2.5 µg/ml 
Fungizone. 
 
6.4. Design of the clinical dehydroepiandrosterone trial (III) 
 
pSS-patients (n=107) were randomized into two treatment groups at the beginning the study 
either to receive DHEA 50 mg q.d. or placebo. The first treatmetn period (4 months) was 
followed by a 1 month long wash-out period. After that, cross-over was performed after 
which the group that had received DHEA in the first treatment period now received placebo 
during the second treatment period (4 months) and vice versa. Patients visited researchers  
1) in the beginning of the study (0 months), 2) after the first treatment period (at 4 months), 3) 
after the wash-out period (at 5 months) and 4) after the second treatment period (at 9 months).  
Compliance was estimated by counting the surplus tablets returned by patient and by 
measuring serum DHEA-S levels at the last visit of the patients (at 9 months).  
 
6.5. Collection of saliva and serum samples (I, III-IV) 
 
The blood samples were let to stand for 45 minutes and then centrifuged for 10 minutes  
(1500 x g). Serum was collected and stored at -20°C.  
 
Unstimulated whole saliva was collected for 15 minutes and stimulated saliva for 5 minutes 
when chewing paraffin capsules. Saliva samples were centrifuged (10 minutes, 100 x g, 
+4ºC), proteinase inhibitor (Complete, Roche, Basel, Switzerland) was added and the samples 
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6.6. Measurement of sex steroid concentrations (I, III-IV) 
 
 Serum levels of DHEA-S were measured with a radioimmunometric assay (Thermo, 
Waltham, MA) (I, III) or ELISA (IBL, Hamburg, Germany) (IV) and serum concentrations of 
DHEA, androstenedione, free testosterone, DHT, 17-β-estradiol and 3α-diol-G with ELISA 
kits (IBL, Hamburg, Germany) (I, IV). 
Total salivary levels of DHEA-S, DHEA, androstenedione, testosterone, DHT, 17-β-estradiol 
and 3α-diol-G were measured with salivary enzyme immunoassays (Salimetrics, State 
College, PA; IBL, Hamburg, Germany) or ELISA kits (IBL, Hamburg, Germany) (I, IV). 
Frozen samples were melted on ice and centrifuged (15 minutes at 200 x g). The clear 
supernatant was used for the analysis. 
 
6.7. Assesment of fatigue and health-related quality of life in 
patients with Sjögren’s syndrome (III) 
 
Fatigue was evaluated using a MFI-20 questionnaire. MFI-20 is a multidimensional self-
report instrument measuring five dimensions of fatigue: general fatigue, physical fatigue, 
mental fatigue, reduced motivation and reduced activity (Smets et al., 1995). In our study the 
MFI-20 questionnaire also included a visual analogue scale (VAS), which measures the 
subjective global fatigue. 
Health-related quality of life was measured either by the RAND-36 or SF-36 questionnaire 
(Hays et al., 1993; Sullivan et al., 1995; Persson et al., 1998; Sullivan et al., 1998) for Finnish 
and Swedish speaking patients, respectively. These questionnaires, however, are almost 
identical. 
 
6.8. Measurement of serum autoantibodies (IV) 
 
Serum autoantibodies (SmB, SmD, RNP-70k, RNP-A, RNP-C, SS-A/Ro52, SS-A/Ro60, SS-
B/La, Cenp-B, Topo-I/Scl-70, Jo-1/HRS, Ribosomal RNP, histones) were analyzed in the 
serum of patients with SS before and after the DHEA replacement therapy. Semi-quantitative 
analysis was done with Inno-Lia ANA Update line-blotting strips (Innogenetics, Gent, 
Belgium) and results were interpretted as negative, borderline, weakly positive, moderately 
positive or strongly positive. 
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6.9. Analysis of messenger RNA expression levels (I-II, V) 
 
6.9.1. RNA extraction and complementary DNA synthesis 
 
Total RNA was extracted from cultured HSG cells with the Trizol method (Invitrogen, San 
Diego, CA), before which cells were washed with PBS. Before addition of the Trizol reagent, 
cells cultured on Matrigel were detached with Dispase (BD Biosciences, San Jose, CA) and 
washed with PBS-EDTA and PBS. From total RNA, messenger RNA was isolated with the 
Dynabeads mRNA Purification Kit (Dynal, Oslo, Norway) (I). 
Alternatively, RNA isolation from the cells was done with RNeasy Mini kit (Qiagen, Hilden, 
Germany) (V). 
From tissue samples total RNA was isolated with High Pure RNA Tissue kit (Roche, Basel, 
Switzerland) (I, III, V).  
The amount and quality of RNA isolated was measured spectrophotometically with Nanodrop 
(Thermo Fisher Scientific, Waltham, MA). 
 
Complementary DNA (cDNA) synthesis for cellular RNAs was performed with SuperScript 
First Strand cDNA Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) from 1500-
2500 ng total RNA or 100 ng of mRNA.  
 
6.9.2. Quantitative RT-PCR 
 
Quantitative RT-PCR (qRT-PCR) was done with LightCycler™ PCR mix and a 
LightCycler™ PCR instrument (Roche, Basel, Switzerland). Serial dilutions of the cloned 
target sequence were used as standards to determine the copy number of the amplicon in 
relation to house keeping genes. Porphobilinogen deaminase (PBGD) was used as 
housekeeping gene in cell experiments and β-actin in tissue experiments. The levels of the 
housekeeping genes were similar in every sample, diverging samples were excluded. All 
primers were designed so that the amplicon covered two exons to facilitate detection of 
possible DNA contaminations. 
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6.10. Western blotting (I) 
 
Cell culture media were concentrated using 10 kDa Centricon centrifugal filter device tubes 
(Millipore, Billerica, MA) and the total protein concentrations were measured with Bradford’s 
method (Bradford, 1976). 
Samples with equal amount of total protein (8.5 -30 µg) were boiled for 5 minutes in SDS-gel 
loading buffer. After electophoresis samples were blotted into Immobilon-P transfer 
membranes (Millipore, Billerica, MA) and blocked overnight with 3 % BSA in Tris-buffered 
saline in room temperature. Membranes were incubated in 3 µg/ml rabbit anti-human CRISP-
3 antibody (Udby et al., 2002) followed by alkaline phosphatase-conjugated secondary 
antibody (Jackson ImmunoResearch, Suffolk, UK). CRISP-3 protein was detected with 
Western Lightning CDP-Star Chemiluminescence Reagent (Perkin Elmer, Waltham, MA), 
followed by imaging of the membranes with ProXpress 2D Imaging System (Perkin Elmer, 
Waltham, MA). Results were quantified using Phoretix software (Nonlinear Dynamics, 
Newcastle upon Tyne, UK). 
 
6.11. Immunofluorescent staining (II, V) 
 
6.11.1. Study II 
 
Labial salivary gland tissue samples were cut to 5 μm sections and fixed in 4% 
paraformaldehyde for 5 minutes. Unspecific binding sites were blocked with 1:10 diluted 
normal donkey serum (Jackson ImmunoResearch Europe Ltd., Suffolk, UK) for one hour at 
room temperature. Tissue sections were incubated in affinity purified primary antibodies 
specific for each intracrine enzyme (1) anti-human steroid sulfatase (STS) E.C.3.1.6.2 IgG 
(Santa Cruz Biotechnology, Heidelberg, Germany), 20 µg/ml, 2) goat anti-human 
sulfotransferase (SULT) E.C.2.8.2.15 IgG (Santa Cruz Biotechnology, Heidelberg, Germany), 
20 µg/ml, 3) goat anti-human 3β-HSD E.C.1.1.1.145 IgG (Santa Cruz Biotechnology, 
Heidelberg, Germany), 20 µg/ml, 4) goat anti-human 17β-HSD E.C.1.1.1.63 IgG (Santa Cruz 
Biotechnology, Heidelberg, Germany), 20 µg/ml, 5) goat anti-human aromatase E.C.1.14.14.1 
IgG (Santa Cruz Biotechnology, Heidelberg, Germany), 20 µg/ml and 6) goat anti-human 5α-
reductase E.C.1.3.99.5 IgG (Santa Cruz Biotechnology, Heidelberg, Germany), 20 µg/ml. 
After the primary antibody, sections were washed in 0.1 % Triton-X in phosphate buffered 
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saline (PBS), pH 7.5, followed by PBS alone. 10 μg/ml donkey anti-goat IgG (Alexa Fluor 
488, Molecular Probes, Eugene, Oregon) was used as a  secondary antibody for one hour at 
room temperature in dark. Next the sections were washed as above and sometimes 
counterstained with 0.014 mmol DAPI (Sigma-Aldrich, St.Louis, MO) nuclear stain in dH2O 
for 5 minutes at room temperature in dark and again washed as above. Finally, sections were 
mounted with fluorescent mounting medium Vectashield (Vector Laboratories, Burlingame, 
CA). Non-immune, normal goat IgG was used instead of and at the same concentration as the 
primary specific IgG antibodies for staining controls. 
 
6.11.2. Study V 
 
Indirect immunofluorescence staining of the integrin type laminin receptors was performed 
with monoclonal IgG1 antibodies TS2/7 against integrin α1 subunit (Hemler et al., 1984) and 
10G11 against integrin α2 subunit (Giltay et al., 1989). Cells were washed in 10 mM 
phosphate buffered, 150 mM saline, pH 7.4, containing 0.1% Triton X-100. Normal goat 
serum (X0907, Dako, Glostrup, Denmark) was used in the blocking step to diminish non-
specific labelling. After incubation with primary antibodies cells were washed in Triton X-
100 containing PBS. Bound antibodies were visualized using secondary goat anti-mouse IgG 
antibody (Alexa Fluor 488, Molecular Probes, Eugene, OR). Propidium iodide diluted 1:1000 
in PBS was used for nuclear staining. After washes in Triton X-100 containing PBS 
coverslips were embedded in fluorescent mounting medium (Dako, Glostrup, Denmark) and 
examined under an Olympus AX70 (Tokyo, Japan) microscope coupled with a CCD camera 
(Olympus DP71). Control immunostainings were performed using non-immune IgG of the 
same sub-class as the primary antibodies at the same concentration as and instead of the 
primary specific antibodies and by using conjugated secondary antibodies alone.  
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6.12. Statistics (I, III-V)  
 
Baseline demographics and disease characteristics were assessed using descriptive statistics. 
Differences in sex steroid levels between patients with SS and healthy controls were tested for 
significance with the t-test or Mann-Whitney U test (for normally and non-normally 
distributed data, respectively). Serum and salivary levels of hormones before and during 
DHEA treatment were compared using Wilcoxon signed rank test and correlations analyzed 
using the Spearman’s test.  
 
The method for cross-over trials by Altman (Altman, 1991) was used for the analysis of 
period effect, period-treatment interaction and treatment effect comparing DHEA and 
placebo. Intention-to-treat principle was adopted for the main analysis. Since the treatment 
was not anticipated to lead to permanent improvement of fatigue, a return to baseline was 
used as an estimate of the true state of the patient in case of discontinuation.  
 
Integrin α1 and α2 mRNA levels without and with androgen and estrogen treatments were 
compared with Mann-Whitney test and the overall effects of stimulations with different 
androgen concentrations studied with Kruskall-Wallis’s test.  
 
All results are given as mean ± standard error of the mean values and median or percentage 
changes from the baseline. The level of significance was set at 0.05 and two-tailed levels of 
significance were used throughout the studies. Data were analyzed with SPSS statistical 
software, Version 13.0 (I), 14.0 (III) or 16.0 (IV-V) (SPSS, Chicago, IL). 
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7. RESULTS AND DISCUSSION 
 
7.1. Systemic and local imbalance of sex steroid levels in patients 
with Sjögren’s syndrome (I)  
 
We hypothesized that patients with SS suffer from androgen depletion. Our hypothesis is 
supported by the facts that the majority of patients with SS are women and that the disease is 
usually diagnosed in patients around 50 years old, simultaneously with decreases in systemic 
levels of estrogens and adrenal steroids (menopause and adrenopause, respectively). To test 
our hypothesis we studied the systemic serum and local salivary hormonal status of SS 
patients and healthy controls. 
 
7.1.1. Systemic sex steroids in Sjögren’s syndrome 
 
Subnormal DHEA(-S) levels in patients with SS had been reported before the thesis studies 
(Valtysdottir et al., 2001; Sullivan et al., 2003; Laine et al., 2007). Like SS, many other 
autoimmune rheumatic diseases such as RA and SLE are female dominant (Beeson, 1994). 
Lower DHEA(-S) levels have been observed also in RA and SLE and patients with rheumatic 
autoimmune diseases are generally considered androgen deficient (Fehér and Fehér, 1984; 
Lahita et al., 1987; Spector et al., 1988; Hedman et al., 1989; Stafford et al., 2000; Sullivan et 
al., 2003; Tengstrand et al., 2003; Imrich et al., 2005). On the other hand, not all studies have 
supported these observations (Cutolo et al., 1986; Brennan et al., 2003; Cevik et al., 2004).  
 
Our hypothesis about the androgen depletion was based on the female dominance, late 
diagnosis and the above-mentioned DHEA(-S) depletion in SS. In addition, salivary glands 
are sexually dimorphic organs and considered a target tissue of androgens with androgen 
receptor localized to the nuclei of acinar and a majority of ductal cells (Laine et al., 1993; 
Treister et al., 2005). As a systemic factor androgen depletion could also explain targeting of 
SS into all exocrine glands of the body. Additionally, the inflammation-reducing effect of 
androgen replacement therapy in salivary (and lacrimal) glands of female SS mice model 
(Sato and Sullivan, 1994) further supports our theory.  
 
 43
Results and discussion 
An androgen deficiency of also other androgens besides DHEA was observed in pSS patients. 
We demonstrated that patients with pSS have significantly lower serum concentrations of 
DHEA-S and DHT compared to age- and gender-matched healthy controls. Also systemic 




Figure 5. Serum concentrations of androgens in patients with Sjögren’s syndrome 
(SS) (n=43) vs. age- and sex-matched healthy controls (n=15). DHEA-S = 
dehydroepiandrosterone sulfate, DHT = dihydrotestosterone. * = p ≤ 0.005. 
 
Interestingly, our group and others have found that serum testosterone levels differ only little 
between SS patients and healthy controls (Valtysdottir et al., 2001; Taiym et al., 2004). 
Testosterone is an “intermediate” between DHEA-S and DHT, both of which are decreased in 
SS, so the minor decrease in testosterone levels could suggest that the conversion of 
testosterone to DHT is ineffective in SS. However, this could also simply be due to the 
relatively wide variation in testosterone values. 
 
Results showing no decreases in serum androgen levels in SS patients (Brennan et al., 2003) 
might be explained by medication. A significant proportion of both patients and healthy 
controls (31% and 47%, respectively) in this study used hormone replacement therapy (HRT). 
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After deletion of these subjects from the analysis, the number of healthy controls was very 
small (n=8), which could have affected the results. Also the concentrations of sex steroids 
were generally notably low in both groups. This could possibly be due to the use of 
corticosteroids, which was not mentioned. Additionally, some studies show no differences in 
the sex steroid concentrations of RA patients (Cutolo et al., 1986, Cevik et al., 2004). If low 
serum DHEA(-S) concentrations play a role for the pathogenesis of pSS, low serum DHEA(-
S) concentrations in RA and SLE could play a role in the pathomechanisms of sSS. However, 
because pSS patients have not been studied prior to the disease outbreak, it is also possible 
that the low systemic DHEA(-S) concentrations are secondary to autoimmune-inflammation. 
 
We also demonstrated that contrary to decresed androgen levels, systemic levels of 17-β-
estradiol were increased in patients with pSS compared to healthy controls (325.6 ± 57.3 pM 
vs. 123 ± 41.9 pM, p=0.008). Accordingly, SS patients have a lowered androgen/estrogen 
ratio. This is in agreement with some previous studies showing increased concentrations of 
estradiol and/or its metabolites in SS and other autoimmune diseases (Lahita et al., 1979; 
Castagnetta et al., 2003; Tengstrand et al., 2003). However, similarly to androgen 
concentrations, the data concerning estrogen levels is conflicting: several studies have found 
no differencies or decreases in estrogen concentrations in patients with autoimmune 
rheumatic diseases compared with healthy controls (Masi et al., 1995; Sullivan et al., 2003; 
Taiym et al., 2004). These results suggest that the estrogen levels vary quite a lot depending 
on the age, menopause and other characteristics of the patients and controls. 
 
7.1.2. Local sex steroids in Sjögren’s syndrome salivary glands 
 
We confirmed the hypothesis about local androgen deprivation in SS and showed that SS pa-
tients consequently have lower salivary secretion of all androgens measured (DHEA, testos-
terone, DHT) compared to age and sex matched healthy individuals (Figure 6). This finding 
fits with our earlier observation, which showed that local levels of DHEA and androgen-
regulated CRISP-3 were decreased in pSS patients compared with healthy controls. CRISP-3 
deficiency was seen all over the glands, also in areas remote of lymphocyte infiltrates imply-
ing that this phenomenon is not caused by infiltrating inflammatory cells (Laine et al., 2007). 
Systemic estrogen excess extended to local level too, with salivary 17-β-estradiol concentra-
tions in SS patients being 22.6 ± 7.5 pM compared to 21.0 ± 1.7 pM in healthy controls 
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Figure 6. Salivary outputs of androgens in patients with Sjögren’s syndrome (SS) 
(n=43) vs. age- and sex-matched healthy controls (n=15). DHEA = 
dehydroepiandrosterone, DHT = dihydrotestosterone. * = p < 0.02. 
 
7.1.3. Eventual causes of systemic sex steroid imbalance in Sjögren’s 
syndrome  
 
Aging influences sex steroid production in humans. In women the production of estradiol 
from the gonads declines sharply at the time of menopause but the production of testosterone 
decreases only gradually (Simpson, 2003; Somboonporn, 2006). In men the age-related 
decrease in the production of androgens is mild and serum concentrations of estrogens either 
show a decline or stay at a steady state (Feldman et al., 2002).  
 
Aging affects also adrenal production of pro-hormones. Serum concentrations of DHEA and 
DHEA-S reach their peak levels between 20 and 30 years, after which they decline steadily in 
both sexes. The most important decline in serum levels of adrenal pro-hormones thus 
precedes menopause and the most common age of SS diagnosis (Orentreich et al., 1984; 
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Labrie, 2003). Adrenopause may be due to age-related atrophy of zona reticularis 
(Pawlikowski, 2005) or decreased secretion of DHEA in response to ACTH, which has been 
reported to decrease with age (Ohashi et al., 1986). Throughout the years, the concentrations 
of DHEA and DHEA-S are higher in men than in women, making women more vulnerable to 
disturbances in sex steroid balance. 
 
Age-related changes lead to decreased levels of both androgens and estrogens. Accordingly, 
we believe that they are not solely responsible for the sex steroid imbalance in SS. Altered 
function of the hypothalamic-pituitary-adrenal (HPA) and/or hypothalamic-pituitary-gonadal 
(HPG) axis has been suggested in the context of autoimmune diseases and lower levels of 
ACTH have been measured in patients with SS. The pituitary and adrenal responses to ovine 
cCRH have been reported to be weakened in SS patients (Tanriverdi et al., 2003; Johnson et 
al., 2006). Also altered production of cytokines may influence the hormonal balance. 
Cytokine environment is disturbed in patients with SS as well as in other autoimmune 
diseases (Brennan et al., 1998; Pflugfelder et al., 1999; Aringer and Smolen, 2004). 
Inflammatory cytokines such as interleukins and TNF-α can down-regulate the synthesis of 
steroid hormones on the adrenal level as seen in chronic inflammations (Herrmann et al., 
2002). In women with SS, the production of DHEA-S from the adrenals has been shown to be 
decreased although the production of cortisol was normal (Valtysdottir et al., 2001). Besides 
cytokines, lymphocytes and macrophages in the adrenal glands could directly influence 
androgen-producing cells of zona reticularis. 
 
7.2. Intracrine machinery in salivary glands (I-IV) 
 
The unbalanced local hormone environment in SS salivary glands might be solely a reflection 
of the endocrine defect seen in SS. Alternatively, it can originate from a distinct local 
intracrine defect. As mentioned earlier, in primates sex steroids are synthesized locally in 
peripheral tissues by intracrine enzymes in addition to gonadal synthesis (Labrie et al., 2005). 
We wanted to study if salivary glands have such a local intracrine sex steroid synthesis 
machinery. In RA mixed synoviocytes such local sex steroid producing machinery has been 
shown (Castagnetta et al., 2003) but to our knowledge, before this thesis the complete 
intracrine potential of salivary glands had not been studied. Thus, our aim was to study the 
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expression and to some extent the function of DHEA processing steroidogenic enzymes in 
salivary glands, both of which we expected to be altered in SS. 
 
7.2.1. Local intracrine enzymatic machinery has an organized architecture in 
healthy salivary glands 
 
We demonstrated that salivary glands are intracrine organs. In vitro studies demonstrated that 
salivary gland cells convert DHEA to more active androgens. This was shown by studying the 
expression of androgen-regulated biomarker CRISP-3 (Laine et al., 2007), which was shown 
to be increased by both DHEA and DHT. However, the up-regulating effect caused by DHEA 
was abolished when the conversion of DHEA further to DHT was inhibited by incubating the 
cells with the potent type I and II 5-α-reductase inhibitor dutasteride. The same phenomenon 
was also suggested in vivo in healthy salivary glands, in which we observed salivary DHEA 
and testosterone not to correlate. In contrast, there was a correlation between salivary 
testosterone and DHT, as if a certain proportion of testosterone would always be converted to 
DHT. However, salivary DHEA levels did not show any correlation with the levels of 17-β-
estradiol either in healthy or diseases glands. These results suggest effective conversion of 
DHEA towards androgens rather than estrogens in salivary glands.  
 
We showed that in healthy salivary glands tubuloacinar epithelial cells contain a complete 
intracrine machinery for DHEA(-S) pro-hormone processing. These enzymes have an 
organized architecture with enzymes processing DHEA in basal parts of the cell. Enzymes 
catalyzing the synthesis of the most active steroids, 5-α-reductase (type I in salivary glands) 
and aromatase, are located in nucleus and apical membrane, respectively (Figure 7A). This 
organization is rational and seems to mirror the preferential site of action for each intracrine 
enzyme. SULT and STS process DHEA and DHEA-S and are thus localized near to the site 
of uptake of DHEA(-S) from the circulation, in the basal parts of the acinar cells. Their 
presence in the tubuloacinar epithelial cells is in line with previous reports showing 
cytoplasmic expression of these enzymes in prostate and ovarian epithelial cells (Okuda et al., 
2001; He et al., 2004). Also the intermediate enzymes, 3- and 17-β-HSDs, were located in the 
basal cell parts. Androgen receptor is located in the nucleus of salivary acinar cells (Laine et 
al., 1993). The nuclear location of DHT synthesizing 5-α-reductase thus enables an effective 
and rapid local production and effects of DHT through the androgen receptor. Aromatase was 
found mostly in the apical membrane of the acinar cells suggesting export of estradiol out of 
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the acinar cells. Since estrogen receptors have been shown to situate mainly in salivary ductal 
cells and oral mucosal epithelium (Välimaa et al., 2004; Tsinti et al., 2009), we think that 
instead of intracrine utilization, estrogens are exported to saliva for further use in the ductal 
epithelial cells. 
 
In contrast to acinar cells, in healthy ductal cells the organization of the intracrine enzymes 
was more diffuse. STS, SULT and 5-α-reductase were expressed more widely and found also 
in the cytoplasm. This was true also with 3- and 17-β-HSDs, which were also found near the 
apical plasmamembrane. Aromatase was in the ductal cells located in both the basal and 
apical plasma membrane. Thus, in salivary ductal cells the organization of the intracrine 
enzymes was not as strict as in acinar cells. 
 
7.2.2. Dysfunctional intracrine machinery in Sjögren’s syndrome salivary 
glands 
 
We showed that the expression and localization of pro-hormone processing enzymes in SS 
salivary glands is disturbed. STS stained very weakly and was relatively diffuse and SULT 
was almost completely absent in SS acinar cells. The expression of 3- and 17-β-HSDs and 5-
α-reductase was more diffuse and staining was observed also further in cytoplasm compared 
with the healthy acinar cells. In contrast to other steroidogenic enzymes, the expression 
pattern of aromatase was not changed in SS (Figure 7B). Thus, the disturbed expression in SS 
seems to affect especially the acinar cells and enzymes participating in the production of 
androgens for local intracrine use, especially that of DHT. This impaired subcellular 
compartmentalization of enzymes participating in the androgen production may explain the 
low local DHT outputs and previous results showing low salivary levels of androgen 
biomarker CRISP-3 in SS salivary glands (Laine et al., 2007). Furthermore, normal 
expression of aromatase might explain the higher outputs of estrogens in SS saliva. In earlier 
studies even increased aromatase expression in labial salivary glands from premenopausal SS 
patients has been shown (Onodera et al., 1998). The activity of aromatase may be increased 
also in patients with SLE and RA (Folomeev et al., 1992; Castagnetta et al., 2003). 
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Figure 7. Local intracrine enzymatic machinery in salivary gland acinar cells in 
healthy individuals and in patients with Sjögren’s syndrome (SS). Panel A: In 
healthy acinar cells intracrine enzymes are organized logically with enzymes 
acting in the beginning of DHEA processing localized in basal parts of the cells 
and dihydrotestosterone synthesizing 5-α-reductase situated in nucleus. Panel B: In 
SS acinar cells expression of androgen processing intracrine enzymes is lower and 
enzymes have lost their architecture. Routes marked with a dashed line are 
impaired leading to lower androgen concentrations. Localization of 17-β-estradiol 
producing aromatase is unchanged. DHEA-S = dehydroepiandrosterone sulfate, 
DHEA = dehydroepiandrosterone, Test = testosterone, DHT = dihydrotestosterone, 
STS = steroid sulfatase, SULT2B1 = sulfotransferase 2B1, HSD = hydroxy steroid 
dehydrogenase, 5-α-R = 5-α-reductase. 
 
At the mRNA level the differences between SS patients and healthy controls were not as 
striking. We used RNA from whole labial salivary glands so we were not able to examine the 
expression patterns specifically in acinar or ductal cells. However, in SS labial salivary glands 
the expression of aromatase mRNA was decreased compared to healthy controls and 
consequently the expression of 5-α-reductase mRNA in SS glands was higher than aromatase. 
Despite that, immunohistochemical staining of aromatase did not show any differencies in 
acinar cells between the healthy and diseased glands. In addition to aromatase, the expression 
of 3-β-HSD mRNA was decreased in SS.  
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Since the expression and localization of the intracrine enzymes in SS labial salivary glands 
were shown to be deranged, we hypothesized that this defect would also be seen in the 
function of this intracrine machinery. We confirmed our hypothesis and showed that in SS the 
correlations between salivary DHEA and testosterone and salivary testosterone and DHT in 
SS, supposed to reflect the situation in salivary glands, were not similar to the healthy glands. 
In SS glands salivary DHEA levels correlated with salivary testosterone levels, which was not 
seen in healthy glands, and at the same time the correlation between salivary testosterone and 
DHT was lower than in healthy glands. The same phenomenon was evident when we 
examined DHEA/testosterone and testosterone/DHT ratios. The former was lower in SS 
patients showing more effective conversion of DHEA to testosterone in SS salivary glands 
than in normal glands. On the contrary, in SS patients the testosterone/DHT ratio was higher 
compared to the healthy individuals suggesting faulty local conversion of testosterone to DHT 
by 5-α-reductase.   
 
Deranged function of the intracrine machinery in SS salivary glands in vivo was seen also as 
an inability to locally convert oral DHEA to active androgens. Previously, oral DHEA 
replacement therapy (50 or 100 mg q.d.) has been shown to lead to increased serum 
concentrations of androgens, but not estrogens, in healthy women. On the contrary, in men the 
concentrations of both androgens and estrogens remained fairly unchanged after DHEA 
treatment (Morales et al., 1994; Morales et al., 1998). Additionally, percutaneous DHEA 
therapy has been shown to have an androgenic but not an estrogenic action in healthy elderly 
women. Moreover, DHEA has been shown to be converted mainly to conjugated metabolites 
such as androsterone-glucuronide (ADT-G) and androstane 3α,17β-diol- glucuronide (3α-
diol-G), which are considered to reflect the intracrine production of androgens better than 
active androgens (Labrie et al., 1997b; Labrie et al., 2007). We showed that the DHEA 
treatment led to normal or to slightly increased serum concentrations of all androgens and 
their metabolite, but the effect on local (salivary) levels of androgens was minor. This absence 
of correlation between serum and salivary androgens in SS is contrary to healthy women, in 
whom the salivary concentrations reflect the systemic concentrations (Swinkels et al., 1988; 
Rilling et al., 1996; Granger et al., 1999; Lewis, 2006; Ahn et al., 2007). 
 
In SS patients serum concentrations of DHT reached the normal values and those of DHEA-S, 
androstenedione and 3α-diol-G even exceeded normal concentrations after the DHEA 
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treatment. Concentrations of free testosterone remained under the reference values even after 




Figure 8. Effect of a 4-month replacement therapy with dehydroepiandrosterone 
(DHEA) (50 mg / day) on serum levels of DHEA-sulfate (A), DHEA (B), 
androstenedione (C), free testosterone (D), dihydrotestosterone (E) and androstane 
3α,17β-diol-glucuronide (F) in patients with Sjögren’s syndrome. Reference values 
are shown in grey background. * = statistically significant. A = androstenedione, 
test = testosterone, DHT = dihydrotestosterone, 3α-diol-G = androstane 3α,17β-
diol-glucuronide. 
 
However, salivary outputs (amount of secreted hormone in 5 minutes) of only DHEA and 
DHT increased significantly (from 5.45 ± 0.82 to 11.14 ± 3.02 pmol, p=0.028 and from 0.91 ± 
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0.20 to 1.44 ± 0.34 pmol, p=0.028, respectively) but the change was clearly minor compared 
to changes in the serum values. Importantly, in some individuals (25%) no increases in local 
androgens were seen at all, besides the increase of DHEA itself (figure 9), although the same 
patients showed increases in serum levels of androgens. Thus, there seem to be differences 
between the individual patients in local androgen processing capacity and in some patients 




Figure 9. Relative changes in salivary levels of androgens after 
dehydroepiandrosterone (DHEA) replacement therapy in patients with Sjögren’s 
syndrome responding (black columns, n=9) and not responding (grey columns, 
n=3) to DHEA therapy. White columns represent baseline levels and are given a 
value of 1. Black and grey columns represent salivary androgen levels after the 
DHEA treatment and are in proportion to baseline values. DHEA-S = 
dehydroepiandrosterone sulfate, A = androstenedione, Test = testosterone, DHT = 
dihydrotestosterone, 3-a-diol-G = androstane 3α,17β-diol-glucuronide. 
 
Our results suggest that the 5-α-reductase defect has a strong effect on the local androgen 
deficiency seen in SS salivary glands. Deficiency of type II 5-α-reductase in humans leads to 
pseudohermaphroditism in males whereas females seem endocrinologically normal 
(Imperato-McGinley and Zhu, 2002). However, as mentioned above, we showed that 5-α-
reductase in salivary glands is of type I, the deficiency of which has not been described in 
humans. 
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7.2.3. Eventual causes of the intracrine defect in Sjögren’s syndrome  
 
One potential disturbing factor in the SS salivary gland intracrinology is the increased 
presence of cytokines, which can disturb the DHEA processing enzymatic machinery as 
mentioned earlier. On peripheral level cytokines are generally considered to increase the 
activity of aromatase and consequently shift the production of active sex steroids towards 
estrogens, as implied also in our study. Cytokines that have been reported to increase the 
activity of peripheral aromatase include TNF, IL-1 and IL-6, among others (Macdiarmid et 
al., 1994; Purohit et al., 1995). The increased activity of peripheral aromatase can lead to 
lower androgen and higher estrogen concentrations in the target tissue of SS. Besides 
aromatase, cytokines affect other steroidogenic enzymes as well. The function of 17-β-HSD 
has been shown to be stimulated by EGF, IFN-γ, TGF-α and TGF-β and that of 5-α-reductase 
by TGF-β1 ja TGF-β2 (Herrmann et al., 2002). Additionally, TNF-α has been shown to 
inhibit the conversion of DHEA-S to DHEA in RA synovial cells and thus cause decreased 
local concentrations of DHEA and further decreased production of active sex steroids from 
this prohormone (Weidler et al., 2005). Cytokines are also considered to direct the 
metabolism of estrogens into 16α-hydroxylated forms, which are proinflammatory (Janele et 
al., 2006).  
 
Besides the function of the DHEA processing machinery, the uptake of steroids into SS 
salivary glands can be affected. The most common route of entry for neutral sex steroids to 
saliva has been considered to be diffusion through the plasma membranes and the acinar cells. 
As mentioned earlier, megalin mediated uptake represents another mechanism for the entry of 
SHBG-bound sex steroids into salivary glands (Hammes et al., 2005). Taking into account 
that the vast majority (98 -99.5 %) of serum sex steroids are bound to SHBG (Dunn et al., 
1981), megalin-mediated transport could be of major relevance for the salivary gland sex 
steroid environment and further for the physiology of these glands.  
 
Uptake of DHEA seems to be normal in SS as shown by elevated output of DHEA after the 
replacement therapy in all SS patients studied. Since the DHEA replacement therapy 
significantly increased the outputs of only DHEA and DHT in SS patients, the existence of 
DHEA and/or DHT binding receptor in salivary glands is possible. Defects in the entry of 
active steroids such as DHT into salivary glands could further ameliorate the local androgen 
depletion caused by the defective local androgen production. This could be the situation in the 
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subpopulation of patients in whom no increases in salivary hormones besides DHEA was seen 
after the DHEA treatment. Active transport is possible also for polarised DHEA-S, which is 
unable to diffuse from circulation to salivary gland cells (Lewis, 2006). Organic anion 
transporting polypeptides such as OATP-2B1 have been suggested to be involved in the 
uptake of DHEA-S into saliva (Pomari et al., 2009). If existing, this active transport could be 
somehow disturbed in SS salivary glands (Figure 10). All together, the expression and 
function of active sex steroid transporters in SS should be studied. 
 
Besides the above-mentioned defective local processing of DHEA and the decreased uptake 
of steroids, low increase in salivary output of androgens might have been due to accelerated 
metabolism of androgens into their conjugates by phase II metabolizing enzymes. However, 
we showed that this is not true in SS salivary glands, shown by the incapability of the DHEA 
treatment to significantly increase the local output of metabolite 3α-diol-G, although its 
systemic concentrations were increased. This demonstrates that increased conjugation of 
androgens is not causing the local androgen depletion in SS salivary glands. 
 
7.2.4. Intracrine defect and the female dominance of Sjögren’s syndrome 
 
Intracrine defect can be detrimental especially for women. As mentioned earlier, the local 
intracrine production of active sex steroids becomes increasingly important in older people, 
especially in postmenopausal women (Belanger et al., 1986; Labrie, 1991). These women are 
deprived of both systemic estrogens and androgens due to the declining function of the 
ovaries and the adrenal gland, respectively. Furthermore, women are more dependent on local 
sex steroid production than men who have testis derived testosterone produced throughout 
their lives. Testosterone is only one enzymatic reaction away from the androgenic and 
estrogenic end products, DHT and 17-β-estradiol, respectively. Women, instead, have first to 
produce DHEA and then convert it to active sex steroids through many intermediates and are 
thus more prone to defects in this local processing. As the conversion of testosterone to DHT 
seems to be defective in SS, testis derived testosterone provides men with more substrate and 
thus possibly protects them against the DHT depletion caused by this SS-related intracrine 
failure. Since most patients with SS are middle-aged women, disturbances in peripheral sex 
steroid production have a significant effect on their local sex steroid levels.  
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Figure 10. Schematic picture of the uptake of androgens in salivary gland acinar 
cell. Neutral steroids such as dehydroepiandrosterone (DHEA) and 
dihydrotestosterone diffuse to epithelial cells whereas polar steroid such as DHEA-
sulfate (DHEA-S) are uncapable of diffusion. Megalin may be responsible for the 
possible active uptake of sex-hormone bingding globulin (SHBG) –bound steroids 
into salivary gland cells and OATP2B1 for the active entry of DHEA-S. In a 
subgroup of patients with Sjögren’s syndrome, characterized with no response in 
local androgen levels to oral DHEA –therapy, megalin- and/or OATP2B1-
mediated active uptake of active androgens and DHEA-S, respectively, might be 
affected (shown in red). On the contrary, the uptake of DHEA seems normal. After 
entering the cell cytoplasm, androges bind to androgen receptor (AR) and regulate 
the transcription of their target genes. SHBG = sex-hormone bingding globulin, 
DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone sulfate, 
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7.3. Effect of androgens on Sjögren’s syndrome related 
characteristics in vivo (I, III-IV) 
 
Androgen deprivation is likely to have various effects on patients with SS. We studied the 
associations between androgens and SS related characteristics and the effects of the oral 
DHEA replacement therapy on these characteristics in SS patients.  
 
7.3.1. Androgen levels reformulate salivation but not autoantibody production 
in Sjögren’s syndrome patients 
 
Many of the earlier studies report decreased salivary flow rates in menopausal women but an 
increase in these rates during HRT, suggesting an influence of estrogens on salivation 
(Eliasson et al., 2003; Yalçin et al., 2005). Also a negative correlation between serum 
estrogen levels and oral symptoms in SS has been reported (Tayim et al., 2004) and some 
studies report no effect of menopause or HRT on salivation (Ship et al., 1991; Eviö et al., 
2006). Association between serum or salivary androgen levels and salivation has been less 
studied. Both lowered salivary levels of DHEA and salivary flow rates have been shown in 
patients with the burning mouth symptom but these two were not correlated either in patients 
or in healthy controls (Dias Fernandes et al., 2009). In a recent study a negative correlation 
between serum testosterone levels and symptoms of dry mouth was shown (Forsblad-d'Elia et 
al., 2009). In the same study, symptoms of dry mouth were shown to relieve after DHEA 
replacement therapy, as has been shown earlier (Pillemer et al., 2004).  
 
In our study, salivary outputs of testosterone, DHT and 3α-diol-G proved to correlate with 
both resting and stimulated salivation and the treatment with DHEA did not affect this 
correlation. Local salivary levels of testosterone and DHT were normalized upon DHEA 
therapy, which emphasizes also the role of a functional intracrine machinery processing 
DHEA further to testosterone and DHT in the function of salivary glands. 
 
Serum levels of androgens and estrogens have been demonstrated to correlate inversely with 
SS-autoantibodies (Forsblad-d'Elia et al., 2009) so we studied the effect of the 4-month long 
DHEA replacement therapy on them in SS patients. However, in our study in most patients no 
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autoantibody response to DHEA was observed, although in 2 out of 12 patients studied there 
was a slight decrease in the titers of SS-A or SS-B autoantibodies.  
 
7.3.2. Dehydroepiandrosterone treatment is not superior to placebo in the 
treatment of fatigue in Sjögren’s syndrome patients 
 
One of the most disturbing and restrictive symptoms in SS is severe fatigue, the reason of 
which is still unknown. Possible causes for SS-related fatigue include defects in the 
autonomic nervous system (Barendregt et al., 1998), cytokines (Baturone et al., 2009) and 
psychological factors such as depression (Barendregt et al., 1998). One potential cause of 
fatigue in androgen deficient SS could be hormonal imbalance. Weak androgens such as 
DHEA have been reported to improve fatigue and wellbeing in the elderly (Morales et al., 
1994) and in Addison’s disease (Arlt et al., 1999; Hunt et al., 2000). Moreover, serum levels 
of DHEA-S, but not testosterone, have been shown to positively correlate with the quality of 
sexual life and mental wellbeing in women with pSS (Valtysdóttir et al., 2003). We 
hypothesized that DHEA replacement therapy could improve fatigue in DHEA-deficient SS 
patients. 
 
DHEA proved not to be superior to placebo in the treatment of fatigue or in improving the 
health-related quality of life in SS patients with severe fatigue and low DHEA-S 
concentrations. Congruently, no correlation between systemic or local androgen levels and 
MFI scores in SS patients was seen. Our results are congruent with previous results (Pillemer 
et al., 2004; Hartkamp et al., 2008), which reported DHEA therapy to be non-beneficial in the 
treatment of fatigue of SS patients. However, the study setting in these studies was completely 
different from our study, in which SS patients had both severe fatigue and subnormal DHEA 
concentrations, and a lower substitution dose of DHEA was used.    
 
These negative results do not exclude the possibility of the contribution of androgen depletion 
to SS-related fatigue. Absence of correlation between androgen levels and MFI scores might 
derive from the great interindividual variation in hormonal levels. Also the aforementioned 
fact that in a proportion of SS patients no signs of local intracrine activity was observed could 
contribute to lack of correlation. However, our results do demonstrate the incapability of oral 
DHEA replacement therapy to improve fatigue experienced by patients with SS. This 
incapability could be explained by defective local processing of DHEA into active sex 
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steroids in peripheral tissues such as salivary glands in SS patients as stated above. If this 
defect is seen also in other peripheral tissues such as brain, it is logical that the restoration of 
the systemic DHEA levels does not lead to restoration of local concentrations of DHT or 
other active androgens in patients with SS. However, one valuable conclusion of our study 
and another study (Hartkamp et al., 2008) is the ability of the placebo treatment to ameliorate 
fatigue and health-related quality of life in pSS patients. This event shows that treatment by a 
specialist and the feeling of a potential to influence the course of their disease can help SS 
patients in controlling fatigue and depression.  
 
7.4. Androgen regulation of laminin-111 and integrins α1β1 and 
α2β1 in salivary glands (V)  
 
Since patients with SS have local androgen depletion in salivary glands, we wanted to study 
the effect of this hormonal imbalance in the target tissue of SS. As mentioned earlier, salivary 
glands are regulated by androgens (Treister et al., 2005) and acinar and ductal cells seem to 
be potential target of androgens in salivary glands (Laine et al., 1993). Accordingly, we 
assumed that androgens are important to the maintenance and function of salivary gland 
acinar cells. Specifically, we hypothesized that androgens affect the interaction between the 
acinar cells and BM through integrins α1β1 and α2β1 and laminin-111, the expression of 
which we have earlier shown to be decreased in SS (Laine et al., 2004; Laine et al., 2008).  
 
7.4.1. Sjögren’s syndrome affects salivary glands  
 
As mentioned earlier, in SS salivary glands are strongly affected. In addition to immune 
infiltrates, central characteristics of SS salivary glands include structural changes, acinar 
atrophy and concordant ductal cell hyperplasia contributing to the diminished secretory 
function.  
 
Accelerated apoptosis of the acinar cells in SS salivary glands has been suggested and could 
lead to redistribution and further to presentation of autoantigens and breakdown of 
immunological tolerance (Ohlsson et al., 2002). However, also studies showing that apoptosis 
of the epithelial cells in SS glands is rare are available, possibly at least partly due to 
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heterogenic patient material and varying methods used in the assesment of apoptosis (Ohlsson 
et al., 2001).  
 
Another potential contributor to acinar cell loss in SS is defective remodelling of SS salivary 
glands. Normally salivary glands remodel continuously and the lost acinar cells are thought to 
be replaced by the migration and differentiation of the relatively undifferentiated intercalated 
ductal epithelial cells (Man et al., 2001). Signals for this acinar transdifferentiation are 
believed to come locally from the underlying BM. In SS, however, this differentiation process 
is believed to be defective. The undifferentiated ductal cells are suggested to divide and 
replace the acinar cells with cells, which due to their inability to differentiate to acinar cells 
retain the intercalated duct cell phenotype (Manganelli and Fietta, 2003). Finally, the outcome 
is acinar cell atrophy and loss and a simultaneous ductal cell hyperplasia (Polihronis et al., 
1998; Man et al., 2001). 
 
Also BM is strongly affected in SS. In the diseased glands disorganisation or patchwise even 
total absence of the BM has been reported, especially in patients with low interacinar fibrosis 
reflecting early stages of the disease (Kwon et al., 2006). BM around ducts and acini has been 
reported to be thinner and glandular structures detached from the basal lamina (McArthur et 
al., 1997; Goicovich et al., 2003). In addition, changes in the acinar specific ECM laminins 
and their cellular integrin receptors (laminin-111 and integrins α1β1 and α2β1, respectively) 
have been reported (Laine et al., 2004; Laine et al., 2008; Velozo et al., 2009). The 
expression of BM modifying MMP-3 and MMP-9 has been reported to be increased in SS 
glands (Konttinen et al., 1998; Perez et al., 2000), which may lead to increased degradation of 
the BM, disturbances in the polarization of the tubuloacinar epithelial cells and to 
dysregulated signaling between the glandular cells and ECM (Garcia-Carrasco et al., 2006).  
 
We hypothesized that androgen depletion could contribute to these pathogenic BM alterations 
in SS salivary glands. Thus, we studied the role of androgens in the structural abnormalities 
involving the acinar BM specific ECM molecules and their cellular receptors (laminin-111 
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7.4.2. Androgens upregulate integrin subunits α1 and α2  
 
We demonstrated that in salivary gland cells and in healthy labial salivary glands androgens, 
but not estrogens, upregulate integrin subunits α1 and α2. These subunits in heterodimers with 
the β1 subunit are central for the communication of acinar cells with its BM through their 
interaction with acinar cell specific laminin-111 (Hoffman et al., 1996). The expression of 
both acinar BM laminin-111 and acinar cell integrins α1β1 and α2 β1 has been earlier shown 
to be diminished in SS salivary glands (Laine et al., 2004; Laine et al., 2008). We thus 
demonstrated a connection between two characteristic features of SS, androgen depletion and 
defects in molecules enabling the signaling between the acinar cells and the acinar BM 
(Figure 11). 
 
The most potent androgenic upregulator of the integrins studied in ductal and acinar cells was 
DHEA, followed by testosterone. The most active androgen, DHT, was not as effective. This 
could be due to non-optimal dose or time points used. Alternatively, the entry of DHT into 
cells by passive diffusion or its active transport could affect the results as could the intracrine 
balance between androgens and estrogens. When the effect of DHEA was studied on tissue 
level, upregulation of integrin subunits α1 and α2 by DHEA was seen in healthy labial 
salivary glands but not in glands from the SS patients, suggesting faulty local intracrine 
DHEA processing in SS as also suggested by our earlier studies. 
 
In addition to androgens, also the contact between the cells and BM extract Matrigel, which 
contains laminin-111, increased the expression of integrin α1 and α2 subunits. This suggests 
that both the contact with laminin α1 chain and the presence of DHEA and its metabolites are 
needed for proper cell-BM-communication. Also the expression of laminin α1 chain by 
epithelial cells was increased by contact with Matrigel, indicative of a self-amplifying 
positive feedback mechanism in laminin α1 chain/-111 expression. This system could enable 
the maintenance of laminin-111 in acinar BMs, which further site-specifically guides the 
progenitor-to-acinar cell differentiation. In contrast to integrins, expression of laminin-111 
was not affected by androgens. 
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Figure 11. Schematic picture representing the connection between laminin-111 
and integrin α1β1/α2β1 and the effect of androgens on integrin expression in 
salivary gland acinar cells. In acinar cells from healthy salivary glands (panel A) 
there is local synthesis of active androgens (testosterone and dihydrotestosterone 
(DHT)) from the adrenal gland derived dehydroepiandrosterone (DHEA). In 
healthy salivary glands androgens, especially DHEA and testosterone, upregulate 
integrin subunits α1 and α2 (shown in the picture with arrows with a thick 
arrowheads). Conversely, in acinar cells from patient with Sjögren’s syndrome 
(panel B) the expression of the acinar specific integrins α1β1 and α2β1 and 
laminin-111 is decreased impairing the communication between the acinar cells 
and their basement memrane. Additionally, androgen depletion, defective local 
androgen processing and faulty androgen regulation of the integrin subunits further 
deteriorates the situation. Int = integrin. 
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Androgen depletion and defective androgen processing in SS salivary glands, combined with 
the lack of laminin-111 and integrins α1β1 and α2β1, impair the signaling between the BM 
and acinar cells. This defect might lead to impaired maintenance of the acinar cells and 
further contribute to the acinar cell atrophy and ductal epithelial cell hyperplasia seen in SS 
salivary glands. Androgen depletion may be the reason behind the deficient acinar 
maintenance caused by disturbances in salivary gland BM and its cellular receptors, which 
have already been reported before (Laine et al., 2004; Laine et al., 2008).  
 
Androgen depletion and defects in the integrin signaling molecules in SS might also account 
for the hypofunction of the SS salivary glands through a different route than by impairing 
acinar maintenance. Laminin-111 participates in the stabilization of synapses (Sugiymama et 
al., 1997; Lee et al., 2002). Thus laminin-111 depletion in SS (Laine et al., 2004), combined 
with defects in its cellular integrin receptors (Laine et al., 2008) could impair the signaling 
between the parasympathetic nerve terminals and postsynaptic muscarinic receptor and thus 
affect salivation in SS salivary glands. 
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8. SUMMARY AND CONCLUSIONS 
 
Etiopathogenesis of SS has remained obscure in spite of extensive research.We hypothesized 
that sex steroids play an important role in the etiopathology of SS and affect the state of the 
diseased salivary glands. Thesis study confirmed our hypothesis and at least to some degree 
clarified the enigma of SS and the status of SS salivary glands by showing that patients with 
SS are androgen depleted. This androgen defect is seen on a systemic level and, even more 
importantly, on a tissue level in the target tissue of SS, salivary glands. Thus, SS patients have 
both a defective endocrine arm and an impaired intracrine arm due to more severe 
adrenopause and defective intracrine machinery, respectively. In contrast to androgen levels, 
systemic and local concentrations of estrogens in patients with SS are slightly higher than in 
healthy individuals thus lowering the androgens-to-estrogen ratio. The importance of the local 
androgen environment to salivary glands is clearly seen in SS, in which salivary enzymes 
participating in androgen production are affected. On the contrary, the expression of 17-β-
estradiol producing aromatase seems to be relatively unaffected. The hormonal imbalance 
caused by androgen deprivation combined with a relative estrogen surplus might predispose 
SS patients to autoimmune aggression.  
 
We believe that especially the local intracrine defect in DHEA processing is central for the 
pathology of SS. We have shown that in SS, unlike in healthy individuals, the effect of 
systemic sex steroid levels on local levels in salivary glands is not straightforward. Therefore, 
our results suggest that the implementation of oral DHEA replacement therapy in the 
treatment of SS is unsubstantial as to the treatment of fatigue and restoration of the local sex 
steroid balance, most probably due to the intracrine failure in local androgen production.  
 
The pathogenetic model of SS should be able to explain the structural changes and the 
diminished function of the affected glands. In this thesis we demonstrated a connection 
between androgen depletion and defects in SS salivary glands. We showed that androgens 
contribute to the expression of acinar cell signaling molecules, integrin subunits α1 and α2, 
through which the acinar cells communicate with the underlying BM. Additionally, we 
showed that local androgen levels, especially outputs of the two most active androgens, 
testosterone and DHT, correlate positively with salivation. Thus, local conversion of DHEA 
further into active androgens has an impact on salivary gland structure and function and 
defects in it can at least partly explain the diminished salivary secretion in SS. 
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Androgen depletion and especially local intracrine defects in SS could also explain the female 
dominance of the disease. Since the local conversion of testosterone to DHT seems strongly 
affected in SS, the testosterone excess in men compared with women provides them with 
more substrate and thus protects men from the eventual endocrine and intracrine defect. 
Women, on the other hand, are more dependent on local DHEA processing and are thus 
predisposed to defects exposing to SS.  
 
Signs of the etiopathology of SS might not be unambiguous. SS patients seem to differ in the 
amount of the intracrine defect in salivary glands: some patients did not have any processing 
of DHEA further to active androgens, referring to more severe local androgen defect, whereas 
in the majority of patients some intracrine activity was seen.  
 
Finally, primary and secondary forms of SS presumably differ in their etiologies. We believe 
that the local intracrine defect affects the exocrine glands of pSS patients. When the systemic 
concentrations of androgens remain sufficiently high, glands are fed with enough pro-
hormones and active androgens and acinar maintenance and function are ensured. However, 
when menopause and a concomitant early and/or more severe adrenopause take place, 
glandular welfare is shaken, pathological processes are induced and symptoms appear. sSS, 
on the contrary, could derive from the inflammation-related reduction in the adrenal 
prohormone synthesis. Long-lasting inflammation and associated cytokines can damage the 
adrenal cortex and decrease the amounts of DHEA(-S) and androstenedione secreted. A 
systemic androgen deficiency would follow leading also to local androgen depletion in 
salivary and other exocrine glands, predisposing the affected glands to autoimmune attack. 
We thus believe that pSS is caused by a local intracrine androgen deficiency, the level of 
which varies between individuals, whereas sSS might represent a secondary deficiency 
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